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ABSTRACT
Anabaseine has demonstrated a high, non-selective, affinity for the α7bungarotoxin sensitive neuronal nicotinic acetylcholine receptor binding site
found in small cell lung carcinoma. The benzylidene anabaseine derivatives of
anabaseine have shown a selective affinity for these binding sites. These studies
suggest that radiolabeled benzylidene anabaseine derivatives could act as
potential imaging agents to aid in the early detection of lung cancer.
This dissertation outlines the strategy and methods employed in the
synthesis of a family of potassium trifluoroborate derivatives of benzylidene
anabaseine and their subsequent halogenation. Two of the trifluoroborate salts
were converted to their radiolabeled analogues for potential use as single photon
emission tomography (SPECT) agents through incorporation of iodine-123, or
positron emission tomography (PET) agents, using bromine-76, for the early
detection of lung cancer. One derivative, 5-[123I]-iodo-2,4-dimethoxybenzyidene
anabaseine was employed in an investigation using a new hamster lung tumor
model.
En route to the synthesis of the radiolabeled benzylidene analogues, an
investigation into a convenient synthesis of anabaseine was conducted. The
synthesis was achieved in four steps and in high overall yields.
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Chapter 1 Introduction
1.1 EMISSION TOMAGRAPHY
Positron emission tomography (PET) and single photon emission
tomography (SPECT) are two research and diagnostic techniques used in nuclear
medicine. The development of SPECT and PET has played an important role in
the study of physiological events and the diagnosis of a multitude of diseases in
vivo. Neurology, 1, 2, 3, 4, 5 cardiology, 6, 7, 8, 9 and oncology, 10, 11, 12, 13 as well as a
multitude of human disorders,14, 15, 16, 17 have been investigated using SPECT and
PET techniques. A brief introduction to these techniques and their significance
for this dissertation is outlined in the following sections. A more detailed
description can be found in chapter 2.

1.1.1 Single Photon Emission Computed Tomography
Single photon emission computed tomography (SPECT) utilizes gamma
emissions from compounds containing radioactive isotopes such as iodine-123,
thallium-201, gallium-67, indium-111, and technetium-99m. The half lives of
these isotopes range from 6 – 67 hours and have emission energies ranging from
140 – 245 keV. SPECT enables in vivo monitoring of physiological events by the
use of a gamma camera which detects the gamma emissions from one of the
radioactive elements that has been incorporated into a designed organic
compound and administered to a patient. The gamma camera acquires multiple
images, or projections, from several different angles, usually using a 360º
1

rotation. A tomographic reconstruction algorithm of the multiple projections
acquired is then applied by a computer to derive a 3D image.18
This dissertation describes the synthesis and use of iodine-123 labeled
compounds as potential SPECT agents to be used as an investigative tool for the
detection of small cell lung carcinoma.

1.1.2 Positron Emission Tomography
Positron emission tomography (PET), as the name suggests, involves
radioactive isotopes which decay by emission of a positron. Oxygen-15, carbon11, nitrogen-13, fluorine-18, Iodine-124, and bromine-76 are a few of the
radioactive isotopes used for this procedure. Due to their relatively short half
lives (excluding iodine and bromine), these radioactive isotopes are normally
produced at or near the PET facility in a cyclotron and then incorporated into an
organic compound before being administered to a patient. Shortly after the
radioactive nuclei emits the positron, the positron annihilates after collision with
an electron from a nearby atom producing two annihilation photons, or gamma
rays, which travel in opposite directions at 180º. Each of the gamma rays has a
characteristic energy of 511 keV. The gamma rays can then be detected by a
dedicated PET scanner, for the best resolution, but can also be detected by a dual
head gamma camera modified for coincidence detection.19, 20
This dissertation describes the synthesis and use of bromine-76 and
iodine-124 labeled compounds as potential PET agents to be used as an
investigative tool for the early detection of small cell lung carcinoma.
2

1.2 SMALL CELL LUNG CARCINOMA
Lung cancer is the leading cause of cancer deaths in American men and
women. The American Cancer Society has estimated for 2006 that 174,470 new
cases of lung cancer will be reported and 162,460 people will die from lung
cancer.21 Small cell lung carcinoma (SCLC) is a very aggressive type of lung
cancer and is strongly associated with smoking. SCLC accounts for
approximately 15% of all lung cancers and is malignant by definition. Having a
more severe prognosis than other types of lung cancer, SCLC is usually metastatic
on presentation making it difficult to cure by surgical removal. If untreated, a
SCLC patient generally survives less than 3 months.22, 23
Current diagnostic screening procedures for detecting cancer, including
SCLC, usually begin with a chest x-ray. A chest x-ray is not an infallible
screening method because lesions smaller than 1 cm may not be detected. If a
lesion is detected, a follow-up histological analysis of a bronchoscopic biopsy is
generally used for an accurate diagnosis. Further testing by means of a CT scan
(computed tomography scan) or a PET scan is normally conducted to investigate
the dissemination of the cancer.23
PET has been used as a diagnostic tool in pulmonary abnormalities and as
a follow up to therapy of non-small cell lung carcinoma cases, the other main type
of lung cancer. At present, PET scans are not recommended specifically for lung
cancer screening because not all malignancies test positive on PET scans using
the currently available PET pharmaceuticals and some benign lung infections
have tested positive.24 The goal of this dissertation research was to improve the
3

accuracy and precision of a PET or SPECT scan in the screening of lung
carcinoma, specifically SCLC lesions smaller than 1 cm. By developing new
radiotracer compounds that have been designed to bind to specific malignancies,
the PET or SPECT scan will become a much more powerful tool in the diagnosis
of specific types of lung cancer and enable more accurate treatment plans to be
employed earlier than current diagnostic radiotracers allow. The following
section provides background information about the research which led to the
choice of the target molecules as potential radiotracers specific for SCLC.

1.2.1 α7-Nicotinic Acetylcholine Receptor
Nicotinic acetylcholine receptors are responsible for regulating the flow of
positive ions into cells by opening small pores in the lipid membrane upon
binding of a neurotransmitter. The opening of the pores allows for the passage of
small ions across an electrochemical gradient. Nicotinic acetylcholine receptors
(nAChR) are found throughout the body. The distinction of the variety of
nicotinic receptors is determined by the type of five possible receptor subunits in
its composition.25 There are 16 known nAChR subtypes, α1- α 9, β1- β4, γ, δ, and
ε.26
Schuller et al. have shown that SCLC contain nAChR composed of α7
subunits (α7-nAChR) having different characteristics than nAChR’s found in
other subtypes of lung cancer, specifically peripheral adenocarcinoma (PAC)
which develops in a significant number of non-smokers.27 Assays performed on
both types of lung cancer determined that carcinogenic tobacco-specific ligands
4

will bind only to the α7-nAChR found in SCLC and not to the α7-nAChR found in
PAC – suggesting why SCLC is strongly associated with smoking. This research
also suggests that further investigation of non-carcinogenic ligands which bind
specifically to nAChR’s in SCLC could lead to the development of radiotracers
that will enable a faster and more accurate diagnosis of SCLC.

1.3 α7-NICOTINIC ACETYLCHOLINE RECEPTOR BINDING LIGANDS
A number of ligands have been proven to bind to the α7-nAChR including
anabaseine, epabatadine, α-bungarotoxin, nicotine, and benzylidene anabaseine
derivatives.27, 28, 29, 30 Of these ligands, the benzylidene anabaseine derivatives
have proven to be selective, specifically for the α7 subtype.29 This dissertation
outlines the synthesis and radiolabeling of a family of benzylidene anabaseine
derivatives for an investigation of their potential use as diagnostic agents for
SCLC.

1.3.1 NNK [4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone]
Schuller et al. have shown that exposure to 4-(methylnitrosamino)-1-(3pyridyl)-1-butanone (NNK), a tobacco carcinogen, up-regulates the α7-nAChR of
normal pulmonary endocrine cells or origin of SCLC.27, 28 This dissertation
outlines the first experimental results of benzylidene anabaseine used as
radiotracers for the detection of lung cancer derived from NNK in hamsters.
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Chapter 2 Literature Review
2.1 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY
This section provides a history and overview of the diagnostic technique
known as SPECT.

2.1.1 Historical Perspective of SPECT
The pursuit of the idea of utilizing radioactive nuclei as diagnostic tools
began maturing in the late 1940’s. At this time the U. S. government revealed the
Manhattan Project and announced the availability of a large variety of
radioisotopes from its uranium chain reaction pile were to be used for scientific,
medical, and technical applications.32 The first step for medical applications
required improvement in efficiency of radioactivity detectors. The GeigerMueller counter was the first type of detector used in measuring γ ray emissions
in biological systems. The counter was equipped with suitable lead shielding to
induce collimation and prevent back-scattering.33 The drawback of the GeigerMueller counter was its low sensitivity, requiring doses up to 200 µCi of
radiotracer for test scanning on animals.
In 1911, Earnest Rutherford published an article giving insight to
experiments done by Geiger et al. involving scintillations caused by radioactivity.
When α particles were diffusely reflected from thick layers of different types of
metals, the number of scattered particles were measured by scintillations, or light
flashes on a zinc sulfide screen.34 A scintillation detector for γ emissions was
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developed in 1947 when Kallmann attached naphthalene crystals to the face of a
photoelectric tube. The crystals absorbed the γ rays and the photoelectric tube
amplified and converted them to electrical pulses, improving the efficiency of
detecting γ emissions.35 Cassen et al. improved upon this idea for γ detection
within biological systems in 1949 by using a scintillation probe consisting of
calcium tungstate crystals on a side-window photomultiplier tube. The
sensitivity, in comparison to the Geiger Mueller detector, was improved
significantly, requiring tracer doses as low as 10 µCi for scanning thyroid glands
in rabbits. This scintillation device became known as the rectilinear scanner. The
name was derived from the detector which moved in straight lines in a raster-like
motion while a dot making device connected to the detector marked dots on a
matrix representing the spatial orientation of γ emissions detected.36
Further improvements to the original design of the scintillation detector
included the replacement of the side-window photomultiplier tube with an endwindow tube and the replacement of calcium tungstate with sodium iodide
crystals. The original printing device required a typewriter ribbon which was
replaced by a thermal-sensitive teledeltos paper that was marked from the heat of
an electric current. The original detector required manual movements via cranks
which were replaced by a dual motor. The most notable improvement occurred in
1956 when Kuhl et al. used a glow lamp and x-ray film as a printing device.
Instead of acquiring a printout of black and white dots, different shades of
intensity were recorded depending on the intensity of the glow lamp in response
to the signal being delivered from the detector. A more picturesque image
7

with greater resolution was the result.36
A major drawback to the rectilinear camera was the extended time
required to scan the entire area of interest because the detector was focused on a
point, and each point of interest had to be covered individually by the detector.
This led Hal Anger, a colleague of Cassen, to devise his “Anger scintillation
camera” which detected all of the points of interest at the same time by the use of
a collimator, a large NaI(Tl) crystal, a photomultiplier tube array, and a cathode
ray tube display. The Anger camera eventually replaced the rectilinear scanner in
the late 1970’s, and has since been improved upon. A modern version of the
Anger camera is still used for SPECT scans today.37
The development of the rectilinear scanner clearly played an important
role in the evolution of diagnostic nuclear medicine. In 1973 alone, after mass
production of the rectilinear scanners, over 2.5 million diagnostic scanning
procedures were performed.38 In this same year, the first article explaining
computerized transverse axial scanning (tomography) was published by
Hounsfield who was eventually awarded a Nobel Prize for his work. The concept
was based on emission reconstruction tomography, a technique introduced by
Kuhl and Edwards ten years earlier.39 Computerized transverse axial scanning,
later known as the computed axial tomography (CAT) or simply computed
tomography (CT), consists of placing a patient between an X-ray source and
scintillation detector, both connected to the same frame. X-ray scans were
administered linearly, recording 160 transmissions. After recording 160
transmissions, the apparatus was rotated 1 degree and another 160 transmissions
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were taken. The process was repeated for 180 degrees. Each of the transmissions
was stored on a disk to eventually processed by a computer based on the intensity
of the X-ray source and intensity of the detection of each transmission. The
resulting image could then be viewed on a cathode ray tube.40
Prior to the use of the computer, images were obtained directly by a form
of print-out that was connected to the scanner. By having the scans saved to a
computer disk in a digital format allowed for multiple types of mathematical
experimentation to be performed in an attempt to enhance resolution and image
quality. Sensitivity and attenuation, the loss of intensity of a photon as it passes
through an absorbent, were improved by means of applying mathematical
algorithms devised by the mathematician Johann Radon, responsible for the
Radon transform algorithm used in attenuation compensation and filter back
projection.41 Cormack, who shared the Nobel Prize with Hounsfield, applied the
mathematics of the late Radon and described its potential for the determination of
a variable x-ray absorption coefficient in two dimensions (CT), and the
determination of the distribution of positron annihilations in matter (PET) .42
There have been scores of contributions to this idea since its discovery, including
its application in SPECT. John Keyes, a colleague of Hounsfield, developed the
first general purpose SPECT camera in 1976.43

2.1.2 Principle of SPECT
Unlike a CT scan which uses an external radiation source, SPECT images
are acquired from internal sources of radiation via an injected or ingested γ9

emitting radiotracer designed to bind to specific biological targets. The
radioisotope used in the radiotracer may be made on location if a cyclotron is
available, or shipped from various locations due to the generally longer half lives
of γ-emitters. There are two types of SPECT devices currently in use,
longitudinal and transaxial. Longitudinal devices are equivalent to the rectilinear
scanner in that they record images in one plane while transaxial devices have the
ability to rotate around the target to record images in slices at a 360 degree
rotation (dual camera systems only need to rotate 180 degrees). Transaxial
devices typically employ a 360 degree rotating Anger camera to detect γ
emissions which are then subjected to tomographic reconstruction to produce a
3D image.44
Although it has been improved upon since its invention, the modern Anger
camera is very similar to its original design. A collimator is used to project γ rays
to a single NaI crystal doped with thallium that measures 11 to 20 inches in
diameter and 0.25 to 0.5 of an inch in thickness. The γ rays are absorbed into the
crystal inducing scintillations which travel in all directions and are received by an
array of photomultiplier tubes. The photomultiplier tubes amplify and convert the
scintillations into electric pulses. A thin light pipe placed between the crystal and
photomultiplier tube array is sometimes used to enhance the scintillations and
increase resolution. Any scintillation can be detected by more than one
photomultiplier tube, but the tube closest to the scintillation will result in the
strongest pulse. The electric pulses pass through position logic circuits to be
converted into position output signals X+, X-, Y+, and Y-. A pulse height analyzer
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determines the Z signal, or pulse height, which represents the intensity of the
scintillation. It is determined from all of the photomultiplier tubes involved in its
detection. The signals are digitized and stored on a computer for a tomographic
reconstruction.37, 44 A diagram of the Anger camera is shown in Figure 2.1.

2.2 POSITRON EMISSION TOMOGRAPHY
This section provides a history and overview of the diagnostic technique
known as PET. A comparison of PET and SPECT is also provided.

2.2.1 Historical Perspective of PET
Reports on the existence of positive electrons began to appear in the early
1930’s. Carl Anderson published a 1932 article in Science describing the
phenomenon he was witnessing and his potential interpretations.45 Anderson
published a follow-up article 6 months later in the Physical Review which
provided more details about his findings and narrowed the potential
interpretations to one explanation, the positron.46 Further investigation by Otto
Klemperer in the following two years provided more experimental evidence about
the physics of the positron. In 1934 Klemperer reported experimental evidence
that positrons annihilate with electrons, thus producing two γ-quanta
simultaneously that travel in opposite directions with emission energy of 511 keV
each (see Figure 2.2). This was based on Einstein’s derivation that energy equals
mass times the speed of light squared.47
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Figure 2.1: Diagram of the Anger Camera. Gamma emissions are collimated
into the sodium iodide scintillation crystal. The photomultiplier tubes
enhance and convert the scintillation into an electrical pulse. Circuitry
detects intensities and converts the pulses into positions which are digitized
and sent to a computer.
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Figure 2.2: Diagram of the Annihilation Reaction. A positron, e+, travels
randomly for approximately 3mm before annihilation with an electron. The
result is two γ emissions in opposite directions each having energy of 511 keV
each.
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By 1951, two years after the invention of the scintillation detector,
researches from Duke University published the first account of utilizing
coincidence detection for the positron’s annihilation reaction.33 The report
demonstrated that coincidence detection of both of the γ-quanta without the use of
a collimator could result in the localization of a radiation source within a skull. In
the same year, researches from Massachusetts General Hospital (MGH)
demonstrated that coincidence detection from a positron emitting nuclei (Na-22)
was more precise than that of a single detection of a beta emitting nuclei (I-131).48
The advantage of coincidence detection was noted immediately in both cases scattered γ rays were eliminated and simple geometry could be used to locate the
radiation source without the use of a collimator. The sensitivity, therefore, could
be increased dramatically as compared to detectors equipped with a collimator.
Brownell et al. from MGH pursued the idea and began development of the
first positron imaging device in the early 1950’s. By 1953 they had constructed
and published results of localizing brain tumors from a crude instrument utilizing
coincidence detection that produced two dimensional images of a positron
source.49 The instrument used a single pair coincidence detector system with
mechanical motion and a printing device. Although the detectors used were still
equipped with a lead collimator, the sensitivity proved to be adequate.
By the mid 1960’s a number of contributions to the concept of coincidence
detection had been made. In particular, Hal Anger had devised his version of the
positron scintillation camera. As described in a Science publication from 1964,
Anger used a coincidence detection system utilizing an Anger camera with one
14

large NaI (Tl) crystal (29 cm in diameter) and 19 photomultiplier tubes with a
focal detector containing 19 scintillation counters, each with separate NaI (Tl)
crystals arranged in a convex orientation. The detectors were connected to an
analog computer that determined the location of the scintillation, its pulse height
(intensity), and whether or not the scintillations occurred in coincidence. If the
scintillation was determined to have occurred in coincidence and the intensity was
strong enough to merit recognition, the scintillation was displayed via a position
oriented flash of light on an oscilloscope and recorded on Polaroid film.50
By 1970, Brownell et al. had constructed a new positron camera based on
the concept of two dimensional arrays. The instrument was composed of two
identical detector arrays, each containing 127 small NaI (Tl) crystals, which had
the ability to rotate from vertical to horizontal positions. This enabled focused
imaging on a plane parallel to the detectors and tomographic imaging via the
transverse plane. The data acquired from the camera were processed via a
computer system and provided static or dynamic images.51 This system enabled
Chesler at MGH to apply filter-back projections to the data, the first reported
applications for positron emissions tomography (PET).52
In 1973, the presentation of Hounsfield’s x-ray CT scan marked the
beginning of a new era for PET (see section 2.1.1).39 By 1976, two groups
(Brownell et al. and Phelps et al.) had developed instruments capable of acquiring
and translating data into tomographic images; each was eventually made into a
commercially available version.53, 54 Since these original designs, a number of
improvements have been made to PET instruments. The circular-array detector
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was introduced which improved upon the dual-head, hexagonal, and octagonal
designs allowing the detector to remain stationary during a scan. Block detectors
were incorporated into the camera design which act as small gamma cameras to
improve detection efficiency and resolution. The NaI (Tl) scintillation crystals
have been improved upon multiple times, first with bismuth germanate, then
lutetium oxy-orthosilicate, and most recently, gadolinium orthosilicate.55 An
overview of a modern PET instrument is provided in the next section.

2.2.2 Principle of PET
Positron emission tomography utilizes positron emitting radioisotopes to
enable monitoring of physiological events occurring in a mammalian body in
vivo. The first step in the process of obtaining a PET scan involves the generation
of a positron emitting nucleus via a cyclotron. Since most positron emitting
nuclei have half lives that are very short lived, a cyclotron is normally located at
or near the PET facility. Positron emitting radioisotopes of longer half lives (12
hours or more) may be made at various locations and shipped to the facility.
Positron emitters of oxygen, carbon, nitrogen, fluorine, copper, iodine, bromine,
iron, gallium, and others have been used in biological studies. Once generated
from the cyclotron, the radioisotope is then incorporated into a biologically active
molecule to become a radiotracer. The radiotracer is then injected into the subject
intravenously. The radiotracer is allowed to circulate throughout the body for an
allotted amount of time dependant upon the type of examination being performed.
The area of interest is then placed into the PET scanner to detect the γ rays
16

emitted from the annihilation reaction of the positron at all angles of 360 degrees.
Reconstruction algorithms are applied to the data to derive an image representing
the source of radiation within the subject.55

2.2.2.1 The Cyclotron
Conceived and invented by E. O. Lawrence in the early 1930’s, the
cyclotron produces accelerated particles with energies measured in millions of
electron volts (MeV) which are capable of inducing nuclear reactions.56 The early
developments in PET were primarily made by a few research groups because few
research facilities were equipped with a cyclotron to generate the short-lived
positron emitting radionuclides. As the significance of PET as a diagnostic tool
became recognized, cyclotrons were constructed for more research facilities.
Most modern PET facilities are now equipped with “baby” cyclotrons designed to
create the most common radionuclides used in PET (11C, 13N, 15O, and 18F).
A typical baby cyclotron for generating positron emitters for PET
produces protons of low energy (10 to 17 MeV) from negative ions of hydrogen.
The negative hydrogen ions are generated by two dee electrodes and are
accelerated from the center of the cyclotron by utilization of a magnetic field at
right angles to the particle’s path. A proton beam is extracted in the cyclotron by
stripping electrons from the negative ion of hydrogen with carbon foils as the
hydrogen atom makes larger and larger orbits from the center of the cyclotron.
The accelerated proton beam is then used to bombard a specific target material
near the outer edge of the cyclotron, inducing a nuclear reaction to generate the
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desired radionuclide.55, 57

2.2.2.2 The PET Camera
Positron emission tomography is dependant upon coincidence detection of
the two γ rays emitted from the annihilation reaction of a positron source.
Optimization of coincidence detection is the fundamental basis for acquiring
sufficient data required for image reconstruction. Ideally, a cylindrical array of
block detectors containing the most advanced scintillation crystals will result in
optimal detection. However, cost concerns have resulted in improvisations
utilizing the most advanced detectors on rotating dual head or hexagonal arrays.55
A modern PET camera detects γ emissions in a similar fashion as the
Anger camera described in section 2.1.2 without the use of a collimator. The PET
camera contains an arrangement of block detectors (cylindrical, hexagonal, or
dual head), each containing an array of scintillation crystals that are viewed by
photomultiplier tubes, Figure 2.3. For example, one type of a bismuth germanate
(BGO) block detector is composed of an 8 x 8 array of BGO crystals (64 total)
prepared by making cuts into one large BGO crystal. The array is viewed by four
photomultiplier tubes. A typical block size is 4 x 4 cm with crystals 4 – 5 mm on
one side.55 The photomultiplier tubes amplify and convert the scintillation into an
electric pulse as well as designate its location by the use of output coordinates
from the electric pulse. The cuts made into the large BGO crystal also help
determine scintillation locations by directing light to the photomultiplier tubes in
more equal proportions. Rows of block detectors are separated by lead disks to
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Figure 2.3: The Block Detector. An 8 X 8 array of scintillation crystals are
viewed by photomultiplier tubes. An assembly of block detectors may be in a
cylindrical form (shown) as well as hexagonal or mounted on a rotating dual
head.
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improve the accuracy of detection by preventing crossing of signals between
rows.
Each photomultiplier tube is equipped with a custom application-specific
integrated circuit (ASIC). These circuits determine the arrival time, position, and
intensity for each analog signal received. The data bits are then digitized by
analog to digital converters (ADC) and time to digital converters (TDC). The
digital signals are then transmitted to a field-programmable gate array (FPGA)
which begins the organizational process for the determination of coincidence
detection by elimination of events that do not correspond to energy emission of
511 keV. The single events that do correspond to energy emissions of 511 keV
are then transmitted to the coincidence processing unit (CPU).58, 59 This circuitry
is diagramed in Figure 2.4.
The CPU searches for single events that have occurred within a time
interval of nanoseconds (3 to10 ns). The time span of nanoseconds may vary
since annihilation events occur off center of the detectors causing one of the two γ
emissions to arrive at a detector before the other. If the time span is too large,
random coincidences may be detected in the allotted timeframe. If the time span
is too small, some coincidences may not be detected due to the different times of
flight of γ emissions from annihilation. This is referred to as timing resolution.
Good timing resolution is strongly dependant on the type of crystal used in the
scanner. The best crystals have a high density and light output with a fast decay
rate resulting in a strong light signal that quickly disappears. The CPU then
coordinates the coincidence events into positions called chords, or electronic
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Figure 2.4: Diagram of Photomultiplier Tube Circuitry. Electric pulses are
sent to the analog ASIC to determine intensity, position, and time of a signal.
The analog signals are digitized by the ADC’s and TDC. The FPGA then
eliminates signals not having an energy of 511 keV.
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vectors drawn between the two crystals involved in coincidence detection. The
chords are then stored on a computer until the scan is complete.60
Once a scan has been completed, a computer software program applies
algorithms to the data to construct an array of 2D sinograms (one per plane) based
on the superimposition of multiple chords from all angles. Corrections for
attenuation, random coincidences, and scattering may be applied to the sinograms.
The corrected sinograms can then be constructed into a 3D image using the filterback projection process.61 A general diagram for a PET scan is shown in Figure
2.5.

2.2.3 A Comparison of PET and SPECT
In comparing PET and SPECT, the first notable difference between the
techniques is the cost of the equipment. A PET scanner may contain up to 3 rings
of 16 block detectors, each block detector being near equivalent to one rotating
SPECT camera.59 The cost of a PET scanner, therefore, can exceed 15 times that
of a SPECT scanner. In addition to the price of a PET scanner, a cyclotron is
usually required on the premises to generate the short lived positron emitters. The
high price of a PET system has lead to lower availability as compared to SPECT.
There are approximately 2,500 SPECT systems in the US, while roughly 50 PET
systems have been installed.62
Despite the cost of the equipment, PET has many advantages over SPECT.
There is a wide range of positron emitting nuclei available for PET, in particular,
the most biologically significant nuclei, 11C, 13N, 15O, and 18F. For SPECT, the
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Figure 2.5: Diagram of a PET Procedure. An annihilation reaction is
detected by a cylindrical array of block detectors. Multiple coincidences are
processed into sinograms. The sinograms are reconstructed into a 3D image.
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best radioactive nuclei are γ emitters, and there are no isotopes of carbon, nitrogen
or oxygen that are specifically γ emitters. As a result, there are considerably more
radiopharmaceuticals available for PET than for SPECT.62
As previously mentioned, the SPECT camera uses a collimator, while a
PET camera does not. A collimator reduces scattered γ emissions and confines
the detection of desired γ emissions to an assigned solid angle. The sensitivity of
the SPECT camera is limited to this one angle of detection, allowing for the
majority of the γ emissions to go undetected. This also affects the resolution of a
SPECT reconstruction. A PET scanner, on the other hand, does not use a
collimator and continuously detects at all angles with systems having rings of
block detectors. The only disadvantage of the PET scanner’s high sensitivity is
“dead time”, or the time when detection is not possible because the circuitry is
backed-up from a large amount of multiple detections.60
The resolution of a reconstructed PET image is clearly better than SPECT.
As mentioned above, the use of a collimator lowers the resolution in SPECT
imaging due to insufficient detection. Another aspect of SPECT that reduces
resolution is that the depth of the radiation source must be known to apply
attenuation corrections efficiently. In the event of annihilation of a positron, the
two photons detected are independent of their source position; therefore,
attenuation correction is independent of the source position in PET. This enables
PET to be used in quantitative studies as well as qualitative. Hence,
pharmacokinetic studies and direct comparisons of tracer uptake can be performed
with PET.63
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2.3 RADIOPHARMACEUTICALS
The following sections provide a brief history of radiopharmaceutical
development and an overview of receptor binding radiotracers used with PET and
SPECT.

2.3.1 Historical Perspective of Radiopharmaceuticals
The dawn of the nuclear age began with an accident caused by an overcast
day in March of 1896. Due to the lack of sun, Henri Becquerel did not have
enough initiating energy to develop his photographic plates. So, he placed them
in a drawer containing uranium and left them overnight. The next day he
discovered that photographically active rays from the uranium crystals exposed
the plates in the dark.64a, 64b The discovery of x-rays by Wilhelm Roentgen which
preceded Becquerel’s discovery of radiation led to the first x-ray photograph.
Roentgen took an x-ray photograph of the bones in his wife’s hand. The potential
medical applications of radiation were picturesque from the beginning, but not
well understood. This is why the discovery of radium by Marie Curie led to the
first medical treatments involving a radioactive substance, radiotherapy. Radium
was used in 1904 in attempts to treat a variety of physiological disorders from
cancer to ringworm.65
Twenty years later, in 1924, the first report of the use of radioactive
isotopes as radiotracers was reported by Sven Lomholt.66 The experiment was
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performed on rabbits using radioisotopes of bismuth and lead. This marked the
beginning of the field of radiology in nuclear medicine.
Fuel for nuclear medical research in the form of a variety of newly
discovered radionuclides became available after Lawrence’s invention of the
cyclotron in the early 1930’s.56 By 1940, artificially radioactive isotopes of
phosphorous-32, iron-59, iodine-128, iodine-130, iodine-131, cobalt-60,
technetium-99m, strontium-89 and carbon-14 had been discovered. Of these
radionuclides, phosphorous-32 was the first radionuclide to be used as a
radiotracer in the form of Na2HPO4.67 The majority of the original medical reports
involving these radionuclides came from the University of California at Berkeley,
or its affiliates, because it the site of the first cyclotron. For example,
Massachusetts Institute of Technology constructed their first biomedical cyclotron
in 1939; prior to its installation, radioactive materials were shipped from
Berkeley.68
The development of radioactive isotopes of iodine marked the beginning
of modern nuclear medicine. Associations with the thyroid gland and iodine can
be traced back to ancient times when the goiter was treated with substances found
in nature which contained iodine. After the discovery of radioactive iodine in
1936, the thought of its application for treatment or detection of thyroid disorders
became a reality.69 Preliminary investigations of radioactive iodine concentrations
in various types of rabbit thyroid glands were reported from Berkeley in 1938 1939 and published in 1940.70 By 1941, radioactive iodine-131 in the form of
sodium iodide was being administered to treat human thyroid disorders.68 These
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investigations marked the beginning of a clear distinction of two separate fields in
nuclear medicine, radiotherapy and diagnosis via radiology.
After World War II, the Manhattan project was revealed and the U. S.
government reported in Science about the availability of large quantities of pure
radioactive elements for use in medical and industrial applications.32 A boom in
nuclear medical research followed this report. Although the methods of detection
were limited to the Geiger-Muller counter at this time, simple radioactive
compounds were used in diagnosis and treatment of biological disorders. For
example, by the early 1950’s, phosphorous-32 in the form of Na2HPO4 was being
used to aid in detection and removal of brain tumors.46 The development of more
complex radiotracers designed for more specific targets began at this time as well.
George Moore published his investigation of the location of brain tumors with
radioactive diiodofluorescein in 1948.71 The iodine-131 labeled human serum
albumin was used to study plasma volumes by Crispell et al. in 1950.72
In 1951, the FDA approved the first radiopharmaceutical, sodium iodide131, for use with thyroid disorders. By 1955, radiopharmaceuticals became
appearing in the United States Pharmacopedeia, indicating the success of nuclear
medical reserach.73 A key to this success was the invention of detectors which
provided a more efficient evaluation of radioactivity in vivo. The historical
backgrounds of the discovery of these detectors are outlined in sections 2.1.1 and
2.2.1.
With the introduction of the rectilinear scanner in 1951, the stage was set
for radiopharmaceutical development. Over the next 50 years,
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radiopharmaceuticals were developed with the same concept in mind – to build
and radiolabel biologically active molecules for specific purposes. A wide variety
of radiotracers have since been developed including receptor binding radiotracers,
the focus of this dissertation, which are described in the next section.

2.3.2 Receptor Binding Radiotracers
In the development of high specific activity compounds labeled with
short-lived radionuclides, a great deal of attention has been focused on receptor
binding ligands associated with cellular communications.74,75,76,77,78 The key to
designing a useful radiotracer of this type comes from understanding the cellular
processes in a normal cell as well as a cancer cell. The cell, under normal
conditions, expresses a variety of receptor systems that involve interactions
between a receptor and its cognate ligand. These interactions are responsible for a
number of processes including cell division, activation or deactivation of
differential activities, senescence, and apoptosis. In a cancer cell, several receptor
systems may exhibit a variety of abnormal behaviors including over-expression of
a receptor, or up-regulation, normally caused by a mutation. Over-expressed
receptors found in tumors may be exploited by designing a radiolabeled ligand
that has high specific activity and affinity for the receptor to enable imaging.78
The process of designing radiotracers for a specific type of cancer has
several stages. The first stage involves the determination of the type of receptors
up-regulated in a specific cancer cell. Generally, in vitro and in vivo evaluations
are performed to make this determination. Once the receptor system has been
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identified, a suitable binding ligand can then be selected to bind to the receptor
system. The ligand should have a high binding affinity for the receptor, a
characterization that can be made by in vitro binding assays. The ligand should
also have specific binding activity only for the receptor being investigated, and
the binding should occur in a timeframe compatible with the radioisotope used for
labeling. Non-specific binding and low affinity binding results in loss of
resolution in nuclear images. After selection and evaluation of a suitable ligand,
the ligand should be synthesized, labeled, and tested in a suitable animal model.
The animal model provides in vivo data regarding the receptor uptake of the
ligand as well as its ability to be displaced by a high affinity antagonist.79

2.4 SCLC AND NICOTINIC ACETYLCHOLINE RECEPTORS
The following sections provide background information about the research
which led to the idea of exploiting nicotinic acetylcholine receptors for the
detection of SCLC.

2.4.1 Lung Cancer
Lung cancer is the leading cause of cancer deaths in American men and
women.21 There are two main types of lung cancer, small cell lung carcinoma
(SCLC) and non-small cell lung carcinoma (NSCLC). SCLC is the less common
form of the two types, but it is more aggressive and carries a worse prognosis.22
The 5-year survival rate for a patient diagnosed with lung cancer is 15%.
However, when the cancer is detected at its earliest stage (pathological stage 1A),
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the 5-year survival rate is increased to 70%.76 The current method recommended
for the detection of lung cancer is a chest x-ray. The chest x-ray has proven to be
an inefficient method for early detection of lung cancer or for increasing the
mortality rate of a lung cancer patient.80 Currently, no medical organization
recommends screening for the early detection of lung cancer due to the lack of
efficient non-life threatening techniques.81, 82

2.4.2 α7-Nicotinic Acetylcholine Receptors (nAChR)
Nicotinic acetylcholine receptors (nAChR’s) are ligand gated ion channel
receptors. The receptors govern the passage of positive ions into a cell through
the lipid bilayer of a cell membrane. The basic mechanism for the receptor is
shown in Figure 2.6. Once a neurotransmitter, or cognate ligand, is bound to the
receptor, a channel is opened and positive ions such as calcium, potassium, and
sodium are allowed to travel down an electrochemical gradient from the exterior
of the cell to the interior.26
The variety of nAChR’s are found primarily in the nervous system
(autonomic, sensory, or central) and skeletal muscle. A nAChR is made up of
five of the 16 known protein subunits which form a pentameric complex. There
are 16 known nAChR subunits, α1- α 9, β1- β4, γ, δ, and ε. Each subunit may
vary in its type; this is the determining factor for the receptor’s function. For
example, a nAChR found in the adult skeletal muscle (Figure 2.7a) contains two
subunits of α1, a β1, ε, and δ.26
The α7-nAChR (Figure 2.7b) is found througout the central nervous
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Figure 2.6: Mechanism of a Neuroreceptor. A neurotransmitter ligand binds
to the receptor embedded in a cell membrane. A ligand-gated ion channel is
then opened. Positive ions of calcium, potassium, or sodium are then allowed
to flow down an electrochemical gradient from the exterior of the cell to the
interior.
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a.

b.
Figure 2.7: Diagram of nAChR’s. a) Diagram of an Adult Skeletal Muscle
nAChR: the electrochemical gradient is centered around five subunits, 2 α1,
β1, ε, and δ. b) Diagram of an α7-nAChR: the electrochemical gradient is
centered around five α7 subunits.
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system and is the most abundant nAChR in the brain. All of its subunits are α7
subunits. This type of receptor is responsible for modulating transmitter release,
generating depolarizing currents, influencing neurite outgrowth, activating second
messenger systems, and facilitating memory. The α7-nAChR is also responsible
for calcium-regulated events and mediating increases of tyrosine hydroxylase
expression.83

2.4.3 Lung Cancer and α7-nAChR’s
Schuller et al. have shown that SCLC contains α7-nAChR having different
characteristics of nAChRs found in other subtypes of lung cancer, specifically
peripheral adenocarcinoma (PAC) which develops in a significant number of nonsmokers.27 Assays performed on both types of lung cancer determined that
carcinogenic tobacco-specific ligands will bind only to the α7-nAChR found in
SCLC and not to the α7-nAChR found in PAC – suggesting why SCLC is strongly
associated with smoking.
Further studies by Schuller et al. have shown that the tobacco carcinogen
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) up-regulates production
of α7-nAChR’s in normal lung cells. This implies that an abnormal abundance of
α7-nAChR’s are located at a SCLC tumor site.28 This research suggests that noncarcinogenic ligands which bind specifically to nAChR’s in SCLC could be used
to exploit this phenomenon for detection of SCLC.
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2.5 BINDING LIGANDS AND RADIOTRACERS FOR α7-nAChR’s
The following sections outline the ligands and radiotracers that have been
developed to bind to α7-nAChR’s.

2.5.1 NNK [4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone]
Both N’-nitrosonornicotine (NNN) and NNK (Figure 2.8) are produced by
nitrosation of nicotine when processed by the mammalian organism. Years of
work has been conducted by Schuller et al. regarding the binding of NNK to α7nAChR’s in the lung. The purpose of their research was to prove that NNK is
indeed the component which induces lung cancer. The results of their research
have led to nearly conclusive evidence that this is the case.85 The hamster model
provided for this dissertation utilizes hamsters exposed to NNK to induce SCLC.
Due to the fact that it is a carcinogen and a non-specific binding ligand, NNK was
not pursued as a potential radiotracer.

2.5.2 α-Bungarotoxin (α-BTX)
Originally obtained from the venom of the banded krait, α-BTX was used
in the first isolation of a nicotinic acetylcholine receptor. The protein α-BTX is a
high affinity competitive agonist for nAChR’s and has been used in their
characterization, localization, and purification. As cloning of receptors became
more proficient, the role of α-BTX has shifted more for the use in comparative
studies. Potential nAChR binding ligands are evaluated based on comparative
binding assays with α-BTX sensitive receptors.85 Labeled derivatives of α-BTX
34

O

N

N
N O

N'-nitrosonornicotine (NNN)

O

N
N

N
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)

Figure 2.8: NNN and NNK. Tobacco carcinogens produced by the nitrosation
of nicotine.
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such as 125I- α-BTX are the most commonly used radiotracers for the
characterization of α7-nAChR’s. However, the labeled 125I- α-BTX does not show
complete binding selectivity for α7-nAChR’s.83

2.5.3 Oxystilbene Derivatives
Investigations of the selectivity of oxystibene derivatives (Figure 2.9) for
α7-nAChR’s have been performed. Although the compound proved selective
specifically for α7 and α8-nAChR’s in chicks, the compound did not show the
same selectivity in mammalian receptors – it bound to various types.86

2.5.4 Nicotine Derivatives
For imaging nicotinic acetylcholine receptors, a labeled nicotine derivative
was an obvious choice for the investigation. Nicotine would not display any
selectivity for the several subtypes of nAChR’s, but detection of its adverse
effects was of interest due to its abundance in tobacco products. Studies began in
1976 with the [11C]-(-)-nicotine derivative to evaluate images of the brain. It was
eventually concluded that labeled nicotine was not a suitable tracer for visualizing
nAChR’s in the brain due to its peak uptake of 1-2 minutes. A variety of other
nicotine derivatives have been investigated (Figure 2.10). It is thought that [123I](S)-5-iodonicotine could be potentially useful for imaging central nicotine
receptors in vivo.75
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Figure 2.9: Oxystilbene Derivatives Tested for α7-nAChR Selectivity.
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5-[123I]Iodonicotine

2.5.5 Epibatadine Derivatives
A series of radiolabeled epibatidine derivatives have been prepared and
investigated for nAChR imaging (Figure 2.11). Epabatidine is an alkaloid
extracted from the skin of an Ecuadorian poisonous frog. Although some
derivatives have proven selective for specific receptors, the toxicity of the
compound has prevented studies on human subjects.75

2.5.6 Pyridyl Ether Derivatives
For examining nAChR’s of the α4β2 subtype, labeled derivatives of the 3pyridyl ethers have proven to be effective. In particular, the labeled derivative of
compound A-85380 (Figure 2.12) has shown noteworthy selectivity for the α4β2
subtype in receptor binding assays87 as well as in actual PET and SPECT
images.83 The goal of the work presented in this dissertation is to achieve similar
selectivity, but for the α7 nAChR subtype.

2.5.7 Quinuclidine Derivatives
A series of quinuclidine derivatives have been synthesized and their
binding selectivity studied (Figure 2.13). The studies determined that compound
AR-R17779 is highly selective for the α7 nAChR over the α4β2 subtype.
Unfortunately, the structure activity relationships have shown that the selectivity
decreases significantly with minor changes in its structure. The labeling of ARR17779 would not only be challenging due to the lack of an aromatic ring on it,
but it would more than likely decrease the selectivity of the molecule. Despite
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Compound AR-R17779 displayed the best selectivity, but structure activity
relationships showed selectivity was lost with slight changes to the structure.
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these results, four labeled derivatives of the quinuclidine were prepared and
investigated for potential PET and SPECT agents (Figure 2.14). None of the
derivatives displayed complete selectivity for the α7 nAChR.

2.5.8 Anabaseine Derivatives
Anabaseine, 1 in Figure 2.5, is a ligand found naturally in some species of
ants and was originally isolated from a marine worm. The toxicity of the ligand is
as mild as nicotine when injected into mice.88 By itself, anabaseine is not
completely selective for the various subtypes of nAChR’s, but an assortment of
benzylidene anabaseine derivatives have shown high selectivity for several
different subtypes, including α7. The structure activity relationships of the
benzylidene anabaseines have shown that binding selctivity can be improved
without significant loss of binding affinity.89 Figure 2.15 shows anabaseine and an
assortment of benzylidene anabaseines that have been investigated.29, 89 The α7
selective derivatives include benzylidene anabaseine, 2, 4-dimethoxybenzylidene
anabaseine, and 4-hydroxybenzylidene anabaseine.
Being affiliated with the radiology department at the University of
Tennessee Medical Center at Knoxville, our group has been interested in the
synthesis of radiolabeled derivatives of benzylidene anabaseines for imaging of
α7-nAChR’s of SCLC. To test if the presence of iodine affected the binding of
the benzylidene anabaseine to an α7-nAChR, a radioreceptor binding assay was
performed. Nicotine and 5-iodo-2,4-dimethoxy benzylidene anabaseine (Figure
2.16), compound 2, competed with [125I]- α7-bungarotoxin (50 pM) for α743
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Figure 2.16: Iodinated 2,4-Dimethoxybenzylidene anabaseine. This iodinated
derivative of benzylidene anabaseine was used in binding assays to determine
that binding selectivity for α7-nAChR’s was not affected by the addition of
iodine to the structure.
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nAChR binding sites. The results of the assay, shown in Figure 2.17, show that 5iodo-2,4-dimethoxybenzylidene anabaseine was more effective than nicotine in
competing with [125I]- α7-bungarotoxin.
To determine if labeled derivatives of benzylidene anabaseine would be
effective as diagnostic imaging agents for SCLC in PET and SPECT, a family of
benzylidene anabaseine trifluoroborate salts was synthesized as non-toxic
precursors for labeling. The details of the synthetic strategies, labeling, and
preliminary hamster model are outlined in the remainder of this dissertation.
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Figure 2.17: Radioreceptor Binding Assay. Nicotine and compound 2
competed with [125I]-α7-bungarotoxin, a site-selective ligand for the α7nAChR, in the human SCLC cells NCI-H69. Similar to anabaseine itself,
compound 2 had a higher affinity than nicotine for the α7 binding sites (EC50
nicotine: 1.05 X 10-8; EC50 compound 2: 1.15 X 10-10).
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Chapter 3 Research Objectives

3.1 SYNTHESIS OF RADIOLABELED ANALOGUES OF BENZILIDENE
ANABASEINE AS SPECT AND PET IMAGING AGENTS
As discussed in section 2.3.2, a suitable receptor radiotracer needs to
exhibit a few necessary characteristics to afford high resolution images in a
SPECT or PET scan. The ligand should have a high binding affinity for the
receptor. The ligand should have specific binding activity only for the receptor
being investigated without binding to other receptors. The binding of the ligand
should occur in a timeframe compatible with the radioisotope being used in the
study. In section 2.5.8, it was shown that derivatives of benzylidene anabaseine
display all of the desired characteristics for binding to the up-regulated α7nAChR’s found in SCLC. It can therefore be concluded that radiolabeled
derivatives of benzylidene anabaseine could be used for the detection of SCLC by
binding to the up-regulated α7-nAChR’s.
This dissertation focuses on the synthesis of potassium trifluoroborate
salts of benzylidene anabaseine derivatives and their subsequent radiolabeling.
This dissertation also presents the preliminary use of the radiolabeled derivatives
as potential diagnostic agents for SCLC in a SPECT scan using a new hamster
model.
Figure 3.1 shows the initial radiolabeled target molecules of the
benzylidene anabaseine derivatives. Two radiolabeled derivatives of 2, 449
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Figure 3.1: Target Molecules. The initial desired target molecules for this
project included the dimethyl and dimethoxybenzylidene anabaseine
molecules with radioisotopes of iodine or bromine on the phenyl ring or
pyridine ring.
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dimethylbenzylidene anabaseine were considered. One derivative contains the
radioisotope at the 5-position of the benzylidene ring, whereas the other contains
the radioisotope at the 5-position of the pyridine ring. Similar derivatives of 2, 4dimethoxybenzylidene anabaseine were considered as well. Consideration was
also given to synthesizing derivatives with the radioisotope on the 6-position of
the pyridine ring, but this was abandoned due to research describing the instability
of 6-pyridyl boronic esters.90 Less substituted derivatives of the molecules shown
in Figure 3.1 were also of interest and included as target molecules.
The three synthetic strategies pursued for obtaining the potassium
trifluoroborate salt precursors are outlined in the following sections. The actual
syntheses are discussed in Chapter 4 - 6. The radiolabeling of the potassium
trifluoroborate salts is discussed in Chapter 7.

3.1.1 Synthetic Strategy A
A general scheme of the first synthetic strategy pursued for the synthesis
of potassium trifluoroborate analogues of benzylidene anabaseine is outlined in
Scheme 3.1. The synthesis involves the conversion of a halogenated benzylidene
anabaseine to a boronic ester. The boronic ester is then converted to the
potassium trifluoroborate. The details of this strategy are discussed in Chapter 5.

3.1.2 Synthetic Strategy B
A general scheme of the second synthetic strategy pursued for the
synthesis of potassium trifluoroborate analogues of benzylidene anabaseine is
51
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Scheme 3.1: Synthetic Strategy A. A halogenated benzylidene anabaseine is
converted to a boronic ester. The boronic ester is then converted to the
potassium trifluoroborate salt.
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outlined in Scheme 3.2. The synthesis involves a condensation reaction between
a benzaldehyde boronic ester and anabaseine to form the boronic ester of
benzylidene anabaseine. The boronic ester is then converted to the potassium
trifluoroborate salt. The details of this strategy are discussed in Chapter 6.

3.1.3 Synthetic Strategy C
The general scheme of the third synthetic strategy pursued for the
synthesis of potassium trifluoroborate analogues of benzylidene anabaseine is
outlined in Scheme 3.3. The boronic ester benzaldehyde is prepared as in strategy
B. Before it is subjected to the condensation reaction with anabaseine, it is
converted to the potassium trifluoroborate. As will be discussed in Chapter 6, this
strategy failed to produce satisfactory results.
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to the potassium trifluoroborate salt.
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Chapter 4 Anabaseine Synthesis

Anabaseine is an essential starting material for the synthesis of the
benzylidene anabaseine potassium trifluoroborate salts. This chapter provides the
details surrounding the synthesis of anabaseine and its derivatives. A background
of the molecule is provided, including its natural occurrences, its original
synthesis, and more recent methodologies employed in its synthesis. The new
synthetic methodology for anabaseine that was developed in our laboratory is
presented.

4.1 ANABASEINE
This section provides background information regarding the isolation of
anabaseine from nature and methodologies employed in its synthesis.

4.1.1 Naturally Occurring Anabaseine
Anabasine is a phytochemical found in the stem of the tobacco plant. It
was shown in a 1966 report that anabaseine is formed from the degradation of
anabasine via a stereospecific dehydrogenation.91 This was the first report of
naturally occurring anabaseine. A derivative of anabaseine was later isolated
from a ribbon worm, Paranemertes, in 1971 by Kem. The compound 3-(pdimethylaminobenzylidene)-anabaseine (Figure 4.1) was found to be the paralytic
toxin which the worm uses to consume polychaete worms larger than itself. The
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toxin was found in three of the five hoplonemertean genera of the worm’s
classification.92 Kem et al. further investigated worms from the hoplonemertean
genera in 1976 and found three other neurotoxins present, including anabaseine
(Figure 4.1).93
The latest report of naturally occurring anabaseine was published in a
1981 issue of Science. Anabaseine was found to be a product of the poison gland
of the Aphaenogaster ants to serve as an attractant.94

4.1.2 Methodologies for Anabaseine Synthesis
Literature examples for the synthesis of anabaseine are outlined below.

4.1.2.1 Synthesis via Claisen Condensation, Hydrolysis, and Decarboxylation
The first documented synthesis of the tobacco alkaloid, anabaseine, was
published in 1936 by Spath and Mamoli.95 Anabaseine, 1, was synthesized as an
intermediate to form anabasine, 3, a similar molecule that differs only in the
saturation of the imine bond of the piperidine ring (Figure 4.2). The structure
provided for anabaseine in the original 1936 publication was incorrect (4 in
Figure 4.2). Without nuclear magnetic resonance (NMR) available for a proper
analysis of the molecule, Spath and Mamoli assumed the location of the double
bond to be between two carbon atoms in the piperidine ring. This mistake was
later corrected with NMR analysis by two Japanese chemists in a 1963
publication (Figure 4.2).96
The methodology used by Spath and Mamoli for the synthesis of
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anabaseine is outlined in Scheme 4.1. Piperidone 5 reacts with benzoic
anhydride,
6, at 180º C to form N-benzoylpiperidone, 7. The N-benzoylpiperidone is then
subjected to a Claisen condensation by refluxing in benzene with dry sodium
ethoxide and ethyl nicotinate, 8, to form intermediate salt 9. After evaporation of
the solvent, the salt is hydrolyzed by heating with hydrochloric acid in a pressure
tube at 130 ºC. Decarboxylation then affords anabaseine dihydrochloride, 10.
The yield of 7 was reported at 56% while the yield of 10 from the intermediate
salt was reported at 36%. Improvements to this method were made by Zoltewicz
et al. to increase the overall yield to 57%.97 A fluorinated derivative of anabaseine
was prepared in a similar fashion, but the overall yield was much lower.98

4.1.2.2 Synthesis via Thermal Induced Rearrangement over CaO
Mundy and Larsen developed a synthetic pathway to anabaseine by
heating N-acylated valerolactams with an equal weight of calcium oxide. The
pathway is shown in Scheme 4.2. Nicotinic acid, 11, is converted to acid chloride
12 with thionyl chloride in pyridine. The acid chloride is then mixed with
valerolactam 13 in pyridine for 15 hours to form acylated lactam 14. The
crystallized acylated lactam is then mixed with an equal weight of calcium oxide
and heated with an open flame until a melt is observed. A reduced pressure
distillation affords anabaseine, 1, in a 62% GC yield. The overall yield could not
be calculated directly since the procedure provided in the article did not provide
specific amounts or yields for the preceding reactions. The same
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reaction was later performed in lower yields (53%) using calcium oxide on
cesium fluoride. The required heat was 250 ºC.99

4.1.2.3 Synthesis via Tertiary Azides
Andrieux et al. performed a condensation reaction with 3-pyridyl lithium,
15, and cyclopentanone, 16, to form 1-(3-pyridyl) cyclopentanol, 17. The alcohol
was then subjected to the Schmidt reaction by conversion to azide 18 by treatment
with hydrazoic acid. The azide intermediate was converted to a heterocyclic ring
with the evolution of nitrogen gas to form anabaseine, 1. The yield of the alcohol
was reported at 80% and the yield of anabaseine was reported at 75%.100 The
synthesis is outlined in Scheme 4.3.

4.1.2.4 Synthesis via Ethylenetetramethyldisilyl-Protected ω-Aminoimines
De Kimpe et al. utilized a synthesis of cyclic imines by using protected
imines as starting materials to acquire anabaseine.101 The synthesis is outlined in
Scheme 4.4. Imine 19 is subjected to α-deprotanation with lithium
diisopropylamide (LDA). Electrophile 20 is then reacts with the deprotanated
imine to form the amine protected intermediate 21. Deprotection of the amine via
methanolysis while refluxing with the presence of potassium carbonate leads to
the cyclization of the imine to anabaseine, 1. The yield from their synthesized
starting material was reported at 88%. The yield for the preparation of the
starting materials was not provided.
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4.1.2.5 Synthesis via Ammonolysis
Daneshtalab et al. synthesized anabaseine by means of ammonolysis of the
corresponding alkyl chloride precursor.102 The synthesis, outlined in Scheme 4.5,
begins with commercially available ethyl nicotinate, 8, and δ-valerolactone, 22.
The resulting condensation product, salt 23, is then subjected to a chloride
assisted decarboxylation to afford the alkyl chloride 24 in 66% yield. Ammonia
gas is bubbled into ethanol with 24 and heated in a sealed vessel at 120 ºC to form
anabaseine, 1, in 67% yield.

4.1.3 Structural Activity Studies for Anabaseine
Although no reports of a structure activity relationship have been
conducted on anabaseine alone, benzylidene anabaseine and nicotine derivatives
have been investigated.103, 104, 105 Section 2.5.8 contains some examples of the
benzylidene anabaseine structures that have been investigated for structureactivity relationships. As shown in figure 3.1, some of our target molecules
contain halogen atoms on the pyridine ring of anabaseine. None of the structure
activity relationships involving anabaseine investigated derivatives with a halogen
on the pyridine ring. However, one report did contain an investigation with
halogenated nicotine derivatives. According to the report, halogen atoms
substituted on the 6-position of the pyridine ring did not affect the binding of
nicotine.105 As noted in section 3.1, boronic esters at the 6-position of a pyridine
have been reported to be unstable, therefore, our research has focused on
halogenations at the 5-position. Based on these reports, it was anticipated that
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anabaseine would tolerate halogenation on the 5-position of the pyridine ring and
that any receptor binding would not be affected by its presence.

4.2 SYNTHETIC STRATEGY FOR ANABASEINE AND DERIVATIVES
As seen in section 4.1.2, there are several available methods for the
synthesis of anabaseine. Of these methods, none have appealing yields. Those
that have acceptable yields require the use of hazardous reagents such as ammonia
gas and hydrazoic acid or do not use commercially available starting materials.
Therefore, our group conducted research to develop a convenient method for the
synthesis of anabaseine and its derivatives. This section outlines our synthetic
strategy.

4.2.1 Synthetic Strategy for Anabaseine
The strategy was derived from the methods outlined in sections 4.1.2.3
and 4.1.2.5. The first step of our synthesis is similar to the first step shown in
section 4.1.2.5; a condensation between the commercially available starting
materials of ethyl nicotinate, 8, and δ-valerolactone, 22, followed by the chloride
or bromide assisted decarboxylation affords the alkyl chloride 24 or bromide, 25.
By conversion of 24 to corresponding azide 26 via nucleophilic substitution with
sodium azide, cyclization via the Staudinger reaction yields anabaseine, 1.106 The
strategy is outlined in Scheme 4.6.
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PPh3

4.2.2 Synthetic Strategy for Derivatives of Anabaseine
Considering the mild reaction conditions required for this methodology
and the targeted molecules noted in section 4.1.3, it was thought that substituents
on the pyridine ring would be tolerated without occurrence of side reactions. Our
research has shown that pyridine substituted derivatives can be integrated into
anabaseine by using the corresponding derivatives of ethyl nicotinate. For
example, synthesis of 5’-bromo-anabaseine, 27, requires the use of 5-bromo ethyl
nicotinate, 28, as starting material. The size of the aliphatic ring is also subject to
modification by variation of the size of the lactone used in the condensation. For
example, myosmin, 29, can be synthesized by using γ-butyrolactone instead of δvalerolactone, 22. Figure 4.3 contains the structures of the various derivatives of
anabaseine and myosmin synthesized by our group using this methodology. The
synthetic details for 1 and 27 are outlined in section 4.3.

4.3 SYNTHESIS OF ANABASEINE AND 5’-BROMOANABASEINE
This section describes the synthetic details surrounding the synthesis of
compounds 1 and 27.

4.3.1 Condensation of Ethyl Nicotinate and δ-Valerolactone
The first synthetic step outlined in Scheme 4.6 involves the condensation
of an ethyl nicotinate, 8 or 28, and δ-valerolactone, 22, to form an intermediate
sodium salt, 23a or 23b (Scheme 4.7). The reactions proceeded successfully in all
cases to form light yellow solids. The salts were not analyzed since
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Figure 4.3: Anabaseine and Myosmin Derivatives Synthesized Using the
Methodology Outlined in Scheme 4.6.
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leads to two separate structures as shown in Scheme 4.7. If the salts are left in
humid air, they begin to decompose to sticky solids and thus were used
immediately in the subsequent reaction.

4.3.2 Halogenation and Competition between Water and Halogen
Upon addition of 48% hydrobromic or 37% hydrochloric acid to 23a or
23b at 110 ºC, two competing reactions took place. The two possible mechanisms
are shown as equation 1 and 2 in Scheme 4.8 using HCl as the example.
Mechanistically, the first step involves a nucleophilic addition to induce
decarboxylation. Normally, water is not a good nucleophile, but its
nucleophilicity is increased when it solvates an anion such as chlorine. By
bearing some of the negative charge of the chlorine anion, water is able to act
more like a Lewis base. In concentrated HCl only 37% hydrogen chloride is
dissolved in 73% water by weight. Therefore, more water is available to act as a
nucleophile than the chloride ion. Also, the chloride ion is not a good nucleophile
in protic solvents when compared to bromide or iodide.
When HCl was used and the reaction is incomplete, the major product
observed was alcohol 35 instead of the alkyl chloride. This suggests that the
reaction shown in equation 1 is most likely the major reaction pathway and the
reaction shown in equation 2 is not occurring. Equation 3 illustrates the formation
of the alcohol. To convert 35 to the alkyl chloride, the mixture was refluxed in
HCl with a slow addition of lithium chloride commencing after refluxing for an
hour. Addition of lithium chloride increases the concentration of the chloride ion
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in the solution and aids in the conversion of the alcohol via the reaction shown as
equation 4 in Scheme 4.8. Similarly, hydrobromic acid reactions did not go to
completion even though the bromide ion is a better nucleophile. Lithium bromide
was used to aid in the conversion to the alkyl bromide.106
The results of the synthesis of four alkyl halide derivatives are shown in
Table 4.1. The yields are moderate, but there is one factor that must be taken into
consideration. The commercial δ-valerolactone used in the reaction may contain
up to 25% of the polymerized product. Daneshtalab et al. calculated their yield
based on the amount of ethyl nicotinate consumed in the condensation.102 This
modification to the yield calculation was not used here. Further investigation into
this reaction may lead to an increased overall yield for the synthesis of the
anabaseines.
Another important property of the alkyl halides should be noted. Neither
compound 24 nor 25 are very stable in air. However, it was observed that
compound 24 is more stable than 25. It is believed that the slight increase in the
electronegativity of the chlorine atom over the bromine atom is sufficient to
prevent the lone pair of electrons on the pyridine nitrogen from acquiring a
hydrogen ion from water in the air. Due to the instability demonstrated by
compound 25, only alkyl chloride 24 was used for synthesis of anabaseine. No
instability was observed by compounds 36 or 37 due to the presence of the
electronegative bromine atom on the pyridine ring.
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Table 4.1: Halogenation of Intermediate Salt 23a and 23b.a
Entry Starting Material

Productb

Acid/Salt

Yieldc (%)

O

1

23a

Cl

HCl/LiCl
N

48

24
O

2

23a

Br

HBr/LiBr
N

51

25

O
Br

3

23b

Br

HBr/LiBr
N

53

36

O
Br

4

23b

Cl

HCl/LiCl
N

a

54

37

All reactions used 20-30ml of acid and 1.1 molar equivalents of lithium salt and were refluxed for
2 hours.
b
All products exhibited satisfactory spectral (1H, 13C NMR) and analytical properties.
c
Isolated Yields
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4.3.3 Nucleophilic Substitution with Sodium Azide
Three of the products in Table 4.1 were subjected to nucleophilic
substitution with sodium azide. The forth, alkyl bromide 25, is not a stable
molecule as noted in section 4.3.2. Since alkyl chloride 24 was stable, it was not
necessary to pursue the unstable alkyl bromide 25 as an intermediate in the
reaction sequence. The azide formation proved to be a relatively simple reaction.
All alkyl halides were converted to their corresponding azides in DMF at 80 ºC in
excellent yields. The results of the reactions are shown in Table 4.2.

4.3.4 Anabaseine Synthesis via Staudinger’s Reaction
The Staudinger reaction has been studied extensively over the past eighty
years.106b Reaction conditions are generally mild and produce excellent yields.
The application of this reaction in the final step of the reaction sequence (Scheme
4.6) to generate the aliphatic heterocyclic ring in anabaseine proved to be
successful. Azides 38 and 39 were mixed with triphenylphosphine in THF with a
microliter amount of water to yield the corresponding anabaseine, 1 or 27 (Figure
4.3), in 96-97% yields. The reactions were performed at room temperature and
allowed to stir overnight (12 hours).
Anabaseine, 1, is a liquid and is very sensitive to air. The compound will
decompose during removal of the solvent if all the solvent is allowed to
evaporate. Bromoanabaseine, 27, is slightly more stable, but it too eventually
decomposes in air. Both molecules 1 and 27 were therefore converted to their
corresponding dihydrochloride salts to increase their shelf life. Each molecule
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Table 4.2: Nucleophilic Substitution with Sodium Azide.a
Entry

Productb

Starting Material

Yieldc (%)

O

1

N3

24
N

95

38

O
Br

2

N3

36
N

96

39
O

Br

3

N3

37
N

a

39

All reactions were ran in DMF and stirred for 12 hours at 80 ºC.
All products exhibited satisfactory spectral (1H, 13C NMR) and analytical properties.
c
Isolated Yields
b
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93

was mixed in isopropanol and a dropwise addition of concentrated hydrochloric
acid afforded the dihydrochloride salt. Ethyl acetate was used to induce
precipitation. The precipitates were filtered and washed with ethyl acetate to give
dihydrochloride salts 40 and 41 (Scheme 4.9) which were air stable and could be
stored for later use.

4.4 SUMMARY
A convenient and mild method for the synthesis of anabaseine and its
derivatives has been developed. The method is satisfactory for generating the
starting material necessary for the synthesis of the target molecules shown in
Figure 3.1. The overall yields for the reaction sequences based on the amount of
ethyl nicotinate average 50%. However, there may be room for improvement
considering the excellent yields of the last two of the three steps in the sequence.
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Chapter 5 Synthetic Strategy A

As discussed in Chapter 3, three potential synthetic strategies were
investigated for the synthesis of the targeted benzylidene anabaseine potassium
trifluoroborate salts. This chapter contains the details of Synthetic Strategy A
outlined in Scheme 3.1.

5.1 SYNTHESES OF HALOGENATED BENZALDEHYDES
Synthetic Strategy A requires halogenated benzylidene anabaseines as
starting materials for the eventual conversion to the boronic esters. Two
precursors are required to obtain the halogenated benzylidene anabaseines,
anabaseine and benzaldehyde. Either the anabaseine or the benzaldehyde may
contain the halogen. Anabaseine and 5’-bromoanabaseine syntheses were
discussed in Chapter 4. The following sections outline the syntheses of various
halogenated benzaldehydes.

5.1.1 Iodination of Benzaldehydes
It has been demonstrated that iodides react faster than bromides in the
conversion of aryl halides to boronic esters in a palladium catalyzed coupling with
an alkoxydiboron (see section 5.3.2). Yield comparisons vary depending upon the
structure and required reaction times. An increased reaction time raises the
possibility for homocoupling, a coupling between the starting material and desired
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product.107 For this reason, iodinated precursors are generally preferred.
There are several known methods for iodinating aromatic compounds.108,
109, 110, 111
113

Two recent methods use iodine monochloride as the iodinating agent.112,

One of these two methods uses a catalyst that must be synthesized.112 The

other uses indium and mercury triflates as Lewis acid catalysts.113 Both of these
methods were derived from the well known reaction of iodine monochloride and
acetic acid at room temperature.114 To avoid using a synthesized catalyst or the
indium and mercury triflates that may be unnecessary, the original reaction
conditions of the well known reaction were employed with a slight modification;
the concentration of acetic acid was diluted with dichloromethane. Although
there have been no examples of iodination of benzaldehydes using this method,
there has been a report of iodination of benzaldehydes with iodine fluoride in 85%
yield.110 Therefore, it was believed that iodination of benzaldehyde would be
possible using this method.
Table 5.1 contains the results of the iodination reactions. Both of the
starting benzaldehydes contained methoxy groups. The aldehyde group is a meta
directing substituent and the methoxy group is an ortho, para-directing
substituent. Therefore, the products were iodinated meta to the aldehyde group
and ortho to the methoxy group. The isolated yield of compound 45 was slightly
lower than that of compound 44. The difference in yield is thought to be due to
the greater reactivity of the dimethoxy substituted benzaldehyde. Also, the
method of purification was different for each compound. Compound 44 was
purified via column chromatography while compound 45 was purified by
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Table 5.1: Iodination of Benzaldehydes.a
Entry

Starting Material

Productb

Time (hours)

O

Yieldc (%)

O
I

1

12

O
O

O

83

O

42

44

O

O
I

2

12
O

49
O

43
a

45

All reactions used 1.4 molar equivalents of iodine monochloride at room temperature. The acetic
acid concentration was 0.35M in DCM.
b
All products exhibited satisfactory spectral (1H, 13C NMR) and analytical properties.
c
Isolated Yields
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filtration because the only chemicals present after work-up were 44 and 43.
Compound 43 is a liquid and compound 44 is a solid which is slightly soluble in
hexanes, the solvent used to rinse the filtrate.

5.1.2 Synthesis of 5-Bromo-2,4-dimethoxy Benzaldehyde, 46
As discussed in section 5.1.1, aryl iodides are the preferred precursors for
generating boronic esters. The synthesis of 46 would therefore seem unnecessary
since the iodinated derivative, 44, had already been prepared. The synthesis of 46
was performed for two reasons. First, a comparison of boronic ester conversion
of iodide and bromide derivatives of benzylidene anabaseine derivatives should
be made to determine if the synthesis occurs readily for each case. If
.no significant difference in yields and reaction times for the boronic ester
conversions of either halide are observed, then the halogenated derivative that is
less costly and more efficiently prepared would be used for larger scale
production. Secondly, when radiolabeling a compound with 76Br, it is necessary
to have the brominated final product available for comparative TLC analysis.
The bromination of aromatic rings is most commonly achieved by
electrophilic aromatic substitution reaction with FeBr3 and Br2. The FeBr3
increases the Lewis acidity of Br2 and enables electrophilic attack. The yield for
this type of reaction is moderate, at best around 50%. After reviewing the
literature for bromination reactions, a mild and efficient method was discovered
using sodium perborate as an oxidant to generate Br2 from HBr.115 Although none
of the examples provided in the publication included benzaldehydes, the reaction
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conditions appeared to be mild enough to tolerate a benzaldehyde.
As outlined in Scheme 5.1, when benzaldehyde 41 was allowed to react
with a mixture of sodium perborate tetrahydrate and 48% HBr in 1,2dichloroethane and tetra-butylammonium bromide for 4 hours at 70 ºC,
compound 46 was obtained in 95% yield after column purification.

5.1.3 Synthesis of 5-Iodo-2,4-dimethyl-benzaldehyde, 47
To acquire the desired dimethylbenzylidene anabaseine target molecules,
Figure 3.1, a halogenated dimethylbenzaldehyde is required. Both iodination and
bromination methods used for the synthesis of benzaldehydes 44 and 46 were
attempted for the synthesis of benzaldehyde 47 from its non-halogenated
precursor. Neither method afforded 47 at room temperature or elevated
temperatures. A large variety of halogenation reactions were performed in an
attempt to synthesize 47 from its non-halogenated precursor without any success.
To obtain compound 47, a five step synthesis was developed. The synthesis is
outlined in Scheme 5.2.
Carboxylic Acid 48 was subjected to a Fischer esterification by refluxing
it for 3 h in methanol with a catalytic amount of sulfuric acid. Ester 49 was
reduced to alcohol 50 with lithium aluminum hydride in THF for 12h at room
temperature. Alcohol 50 was converted to acetate 51 in acetic anhydride with
pyridine for 24h at room temperature. Acetate 51 was allowed to react with
iodine monochloride in methylene chloride and acetic acid for 15 h at room
temperature to afford benzyl chloride 52. A Sommelet oxidation of benzyl
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ICl
CH2Cl2

chloride 52 with hexamethylenetetramine in acetic acid afforded benzaldehyde
47. The overall yield of the reaction was 51%.116

5.2 SYNTHESES OF HALOGENATED BENZYLIDENE ANABASEINE
DERIVATIVES
The following sections provide the synthetic details surrounding the
synthesis of the targeted halogenated benzylidene anabaseine derivatives.

5.2.1 Background of Benzylidene Anabaseines
The first reports of the synthesis of benzylidene anabaseines derived from
Kem’s studies of the sea worm paranemertes.92 The synthesis was achieved by
mixing anabaseine with an excess of benzaldehyde in ethanol at 61 ºC. Further
investigation of the synthesis of benzylidene anabaseines by Kem demonstrated
the successful use of small amounts of acid in an acid-catalyzed aldol
condensation (Scheme 5.3). The reported yields were good, 70 – 87%. The study
also confirmed the structure of the molecule and a lack of isomerization about the
double bond (molecular models suggest isomerization is possible).117 These initial
studies provided synthetic pathways to a family of compounds that have since
been the topic of a plethora of studies involving nAChR binding.29, 89

5.2.2 Syntheses of Halogenated Benzylidene Anabaseine Derivatives
To synthesize halogenated benzylidene anabaseine derivatives, the acidcatalyzed aldol condensation pathway shown in Scheme 5.3 was used due to its
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proven success. Halogenated benzaldehyde derivatives were reacted with
anabaseine dihydrochloride, 40, in ethanol with a few drops of hydrochloric acid
for 3 days at 70 ºC. To acquire the free base, the resulting hydrogen chloride salts
were dissolved in water and deprotonated with triethylamine. Column
purification afforded the pure products which could be stored under an inert gas.
The same procedure was applied to brominated anabaseine dihydrochloride 41
and non-halogenated benzaldehydes. A summary of these syntheses is shown in
Table 5.2. Based on the simplicity of the reaction and the good to excellent
isolated yields, no alternative synthetic methods were investigated.

5.3 SYNTHESES OF BENZYLIDENE ANABASEINE POTASSIUM
TRIFLUOROBORATE DERIVATIVES
The following sections discuss the conversions of halogenated
benzylidene anabaseines to their corresponding trifluoroborate salts.

5.3.1 Background of Organic Potassium Trifluoroborate Salts
Investigations of organic quaternary salts of boron were reported as early
as 1940.118 The physical properties of potassium tetrafluoroborate were reported
in 1954.119 Two key methods for the synthesis of organic trifluoroborate salts
have been reported since investigations of organic trifluoroborate salts began.
The first method involves the addition of 3 equivalents of potassium fluoride to an
arylboron or alkylboron dichloride.120 Although this method was proven to
proceed in moderate to good yields, the synthesis required organoboron dichloride
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Table 5.2: Halogenated Benzylidene Anabaseine Synthesis.a

Entry

Starting
Anabaseine

Starting
Benzaldehyde

Productb

Yieldc (%)

I

1

I

40

N
CHO

53

N

Br

Br

2

40

89

N

CHO

54

N
I

O

O

I

3

40

O
CHO
44

97
N

O
2

N
I

O

O

I

4

89

40
N

CHO
45

55

N

Br

O

O

Br

5

92

40

O
CHO
46

75
N

O
56

91

N

Table 5.2 Continued.

Entry

Starting
Anabaseine

Starting
Benzaldehyde

Productb

Yieldc (%)
I

I

6

90

40
N

CHO
47

57

O

Br

O

7

N

41

N

O
CHO

O
58

95

N

Br

8

41

79

N

CHO

59

a

N

All reactions used 1.2 molar equivalents of benzaldehyde at 80 ºC in ethanol.
All products exhibited satisfactory spectral (1H, 13C NMR) and analytical properties.
c
Isolated Yields
b
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precursors that are very unstable and difficult to handle. The second method
involves the conversion of a stable boronic acid to the corresponding potassium
trifluoroborate salt by addition of inexpensive and stable KHF2 in methanol at
room temperature.121 The yields of this reaction were reported to be good to
excellent. The same reaction has since been proven successful with boronic
esters.122

5.3.2 Synthetic Methodologies for Boronic Acids and Esters
Syntheses of organic boronic acids have been studied extensively. The
synthesis of phenylboronic acid was first reported in 1880.123 Phenylboronic acids
were prepared by reacting boron trifluoride or trimethyl borate with phenylmagnesium bromide followed by hydrolysis as shown in equation 1, Scheme 5.4.
Reported yields for this method averaged 50% at best.124 Similar reactions were
performed with a variety of organometallic reagents, again in moderate yields.125,
126, 127

Previous research in our group improved upon this method by substituting

borane as the boron reagent (equation 2 of Scheme 5.4).128 With this method,
yields were improved to 71% or better for phenylboronic acids. Application of
either of these methods to halogenated benzylidene anabaseines was not
considered due to low yields or the incompatibility of borane with double bonds
due to hydroboration.
A more recent investigation of arylboronic acid syntheses via aryllithium
compounds has shown that yields of the boronic acids can be improved.129 As
shown in equation 3, Scheme 5.4, addition of n-butyllithium to a mixture of an
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MgX + B(OMe)3

B(OMe)3MgX

MgX + BH3

Br

+ B(iPrOH)3

BH3MgX

1. n-BuLi
2. HCl

H2O

B(OH)2

Scheme 5.4: Synthesis of Phenyl Boronic Acids.
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H2O

B(OH)2

B(OH)2

(1)

(2)

(3)

aryl halide and triisopropyl borate followed by an acid quench results in the
corresponding boronic acid in good to excellent yields. The only difference
between this protocol and the original syntheses with aryllithium reagents is the
order of addition. The yields are decreased significantly if n-butyllithium is
added before triisopropyl borate. Although this method affords the desired
boronic acids in high yields, it is not compatible with benzylidene anabaseines.
The α carbon of the imine in benzylidene anabaseine is susceptible to
deprotonation in the presence of a strong base such as n-butyllithium.
Boronic esters can be synthesized from the tetraborate intermediate of the
boronic acid reaction by addition of a diol such as pinacol instead of water which
leads to hydrolysis.129 As already discussed, this pathway is not feasible with
benzylidene anabaseine derivatives. Upon the advent of the Suzuki crosscoupling reaction with aryl boronic esters, 130 considerable efforts hve been
exerted to find a convenient synthesis of these molecules. Miyaura et al. used the
same catalytic system employed for the Suzuki coupling to acquire arylboronic
esters in good to excellent yields.107 The catalytic cycle of the reaction is outlined
in Scheme 5.5. An aryl halide is reacted with palladium (0) via an oxidative
addition to form a palladium (II) complex. Acetate (from potassium acetate)
exchanges with the halide. A diboron ester, typically bis(pinacolato)diboron,
undergoes a transmetalation to form an aryl-palladium-pinacolboron complex.
Reductive elimination gives the aryl boronic ester and the original palladium (0)
catalyst. The palladium catalyst shown to work best for this reaction is

95

Ar B

O
O

Pd(0)

O
Ar

Ar X

Ar

Pd(II) B

Pd(II) X

O

AcO K

O
B OAc

L
Ph Pd OAc
L

O

O

KX

O
B B

O

O

Scheme 5.5: Catalytic Cycle for the Synthesis of Aryl Boronic Esters.
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PdCl2(dppf). A similar reaction has also been demonstrated using pinacolborane
and triethylamine substituted for bis(pinacolato)diboron and potassium
acetate.131The application of this catalytic cycle to benzylidene anabaseines was
investigated and is discussed in the next section.

5.3.3 Syntheses of Benzylidene Anabaseine Boronic Esters
Both catalytic reactions for boronic ester synthesis discussed in the
previous section were applied to the halogenated benzylidene anabaseine 2. As
was anticipated, the use of pinacolborane and triethylamine did not afford the
desired product in sufficient yields. Apparently, hydroboration with
pinacolborane occurs just as rapidly as the catalytic cycle of Scheme 5.5.
However, the use of bis(pinacolato)diboron and potassium acetate in the catalytic
cycle proved to be useful for conversion of 2 to the corresponding benzylidene
anabaseine boronic ester, 60 (Scheme 5.6). Very little reaction progress was
observed after 16 hours at 80 ºC. A slight increase in the reaction temperature to
95 ºC was required for the reaction to be completed within 12 hours.
The boronic ester proved to be extremely challenging to purify. Protic
solvents, such as methanol, hydrolyzed 60 on silica gel, producing a mixture upon
elution from a column. The mobility of 60 on silicon dioxide was practically nonexistent for the majority of aprotic solvents. Acetone and THF were the only
aprotic solvents found to move 60 from the origin of a TLC plate. Even with the
use of polar aprotic solvents, a small amount of hydrolysis was observed upon
elution from a column based on GCMS and NMR analyses. The 1H NMR results
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Scheme 5.6: Synthesis of Benzylidene Anabaseine Boronic Esters.
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O

(Figure 5.1) confirms the hydrolysis after column purification. The singlet at 6.37
ppm corresponds to the hydrogen atom between the two methoxy groups; it is
split into a doublet and shifted slightly downfield (labeled A in Figure 5.1). The
hydrogen atom from hydrolysis is observed at ~ 6.57ppm as a doublet of doublets
(labeled B in Figure 5.1). The splitting pattern results from the hydrogen’s
coupling with two adjacent hydrogens, the hydrogen located meta between the
two methoxy groups (small J) and the hydrogen located ortho (large J). The
example provided is from a spectrum obtained after purification in acetone. The
effect is enhanced significantly if a protic solvent is used. The entire spectrum
can be found in the appendix.
After multiple attempts to isolate the boronic ester in a pure form via
column chromatography, it was decided to synthesize the potassium
trifluoroborate salts of benzylidene anabaseine without column purification of the
boronic esters. The synthetic pathway and results are discussed in the next
section.

5.3.4 Syntheses of Benzylidene Anabaseine Potassium Trifluoroborates
Research performed by our group has shown that organic potassium
trifluoroborate salts can be synthesized in situ from their corresponding boronic
esters.132 The examples provided in the publication, however, do not use DMSO
as a solvent. Solvents with lower boiling points such as THF, ethyl ether, and
toluene were used with palladium catalysts such as Pd(dba)3 and Pd(OAc)2.
Through the use of these solvents, it was possible to separate the organic
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Figure 5.1: Evidence of Hydrolysis of Benzylidene Anabaseine Boronic
Esters.
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potassium trifluoroborate salts from the reaction mixture with relative ease.
DMSO, however, dissolves the trifluoroborate salts and prevents an easy
separation. Therefore, the reaction conditions developed in our laboratories were
attempted with compound 2, but no reaction was observed. The same catalytic
system shown in Scheme 5.6 was attempted with solvents other than DMSO, but
again, no reaction was observed. Therefore, all conversions of halogenated
benzylidene anabaseines to their corresponding boronic esters were conducted
using the conditions shown in Scheme 5.6. The DMSO was then removed via
Kügelrohr distillation. The resulting boronic esters were separated from the
excess of potassium acetate using boiling ethyl acetate. After filtration, the ethyl
acetate was removed under reduced pressure and the residual solid was used in
the next step without further purification.
The conversion of boronic esters of benzylidene anabaseine to their
corresponding potassium trifluoroborate salts proceeded efficiently without the
purification of the boronic esters. The residual solid boronic ester was dissolved
in methanol and 4 molar equivalents of saturated KHF2 were added. The reaction
mixture was stirred in open air for 4 hours. All solvents were completely
removed under reduced pressure and then under high vacuum. Boiling
acetonitrile was used to dissolve the trifluoroborate salt. After filtration, the
solution was concentrated and the residual solid was washed with boiling ethyl
acetate to give the benzylidene anabaseine trifluoroborate salt. The results are
presented in Table 5.3. The isolated yields ranged from 25 to 77%. It should be
noted that the yield of entry 3 should theoretically be the same or better than entry
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Table 5.3: Synthesis of Benzylidene Anabaseine Trifluoroborate Salts via
Synthetic Strategy A.a
O
X

O

B

O

O

BF3K

B B
O

N

PdCl2(dppf)
KOAc
DMSO
80 oC 12h

N

Entry

1

O

N

N

KHF2
Methanol
r.t. 4h

Productb

Starting Material

N

N
53

N

61

N

BF3K

63

N
54

N

62

N

I

BF3K

O

3

N

O

60

O
2

25

N

Br

2

N

Yieldc (%)

BF3K

I

N

N

N

O
63

N
BF3K

I

O

O

4

47
N

N
55

N

64

102

N

Table 5.3 Continued

Entry

Productb

Starting Material
Br

Yieldc (%)

BF3K
O

O

5

77
N

O
56

N

N

O
63

N

I

BF3K

6

50
N

N
57

N
O

Br

7

O

N
58

O

BF3K
N

N

O
66

Br

8

N

65

N

BF3K

N

49

N
59

71

N

67

a

N

All reactions used 0.03 molar equivalents of PdCl2(dppf) catalyst, 3 molar equivalents of
potassium acetate, and 1.1 molar equivalents of bis(pinacolato)diboron in DMSO for the boronic
ester conversion. The potassium trifluoroborate salts were synthesized using 4 molar equivalents
of KHF2.
b
All products exhibited satisfactory spectral (1H, 13C NMR) and analytical properties.
c
Isolated Yields
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5. The deviation may be attributed to the salt being slightly soluble in boiling
ethyl acetate which can result in slight variations of the yield. Due to the
efficiency of bromination demonstrated in section 5.1.2 and the high yield
obtained from its conversion to a potassium trifluoroborate, bromination of 42 is
recommended.

5.4 SUMMARY
The synthesis of benzylidene anabaseine potassium trifluoroborate salts
can be achieved successfully with moderate yields via Synthetic Strategy A. A
total of eight examples were prepared. Despite the inability to purify the boronic
ester intermediate efficiently, the trifluoroborate salts were prepared by taking
advantage of solubility properties. The bromine or iodine benzylidene
anabaseines both proved to be useful precursors to the corresponding potassium
trifluoroborate salts. Therefore, the most efficient halogenation procedure should
be chosen to improve overall yields.
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Chapter 6 Synthetic Strategies B and C
As discussed in Chapter 3, three potential synthetic strategies were
investigated for the syntheses of the targeted benzylidene anabaseine potassium
trifluoroborate salts. The details of Synthetic Strategy B are outlined in this
chapter (Scheme 3.2).

6.1 SYNTHESES OF BENZALDEHYDE BORONIC ESTERS
Synthetic Strategy B contains an outline of the syntheses of benzylidene
anabaseine boronic esters via the condensation of a benzaldehyde boronic ester
with anabaseine. The synthesis of the anabaseine precursors 40 and 41 were
discussed in Chapter 4. The syntheses of a variety of benzaldehyde boronic esters
for use as starting material in Synthetic Strategy B are discussed in the following
sections.

6.1.1 Background for Benzaldehyde Boronic Ester Syntheses
The conversion of aryl iodides and bromides to the corresponding boronic
esters using bis(pinacolato)diboron and a palladium catalyst was discussed in
section 5.3.2. However, there were no examples provided in the literature
utilizing this method using halogenated benzaldehyde precursors. The syntheses
of benzaldehyde boronic esters has been reported by esterification of their
corresponding boronic acids.133 The boronic acid precursors were synthesized
from the corresponding halogenated benzaldehydes by the procedure discussed in
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section 5.3.2, after protection of the aldehyde group.134 The method for
synthesizing the boronic esters based on these reported procedures is outlined in
Scheme 6.1. The reaction sequence involves four steps with overall yields
averaging 65%.
Theoretically, benzaldehyde boronic acids could be used as starting
materials for the reaction sequence desired for Synthetic Strategy B. However,
based on research conducted by Westcott et al., the synthesis of imines from
boronic acids can be exceedingly difficult due to the boronic acids forming
insoluble anhydrides. They found that protection of the boronic acid functionality
by conversion to the corresponding boronic ester enabled imine formation.133 The
reaction sequence of Synthetic Strategy B involves an imine (in anabaseine), but
the imine is present prior to the condensation reaction. The Westcott method
suggested the use of boronic esters is promising. To avoid additional steps
forming the boronic acid or ester via Scheme 6.1, the syntheses of boronic esters
was conducted in one step using the palladium catalytic cycle and a modified
work-up as discussed in the next section.

6.1.2 Syntheses of Benzaldehyde Boronic Esters
After reviewing the strategies available for obtaining the targeted
benzaldehyde boronic esters, the conversion was completed via the palladium
catalyzed diboron reaction (Scheme 5.5). This method is advantageous because it
is rapid (~3 hours) and involves only one step, as opposed to the alternative fourstep procedure, Scheme 6.1. The main concern to applying this method was the
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Scheme 6.1: Literature Procedure for Benzaldehyde Boronic Ester Synthesis.
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sensitivity of the aldehyde group to the reagents. The solvent, DMSO, normally
requires Kügelrohr distillation for its removal. This involves heating the mixture
to 80 ºC under high vacuum. The potential loss of benzaldehyde under these
conditions led to an alternative method for DMSO removal. After completion of
the reaction, the mixture was quenched with brine and extracted with ethyl
acetate. The organic layer was then washed three times with brine (the use of
water instead of brine results in an inseparable emulsion). After concentration of
the dried organic layer under reduced pressure, a trace amount of DMSO
remained, but it could be removed by column chromatography using a non-polar
solvent such as hexanes. Table 6.1 contains the results of the benzaldehyde
boronic esters synthesized utilizing this method. The isolated yields were
moderate to good. Conversion, based on TLC was excellent in all cases except
that of Entry 5, possibly a consequence of steric hindrance by the two methyl
substituents. The low yield shown in Entry 2 was a consequence of a difficult
purification as well as generation of the homocoupling side-product due to the
extended reaction time. The product streaked on a column packed with alumina
or silica gel, but was eventually eluted with 10:1 hexanes: ethyl acetate. Due to
the efficiency of the purification of Entry 1, which was eluted with 10: 1 hexanes:
THF, THF is the polar solvent of choice for the purification of boronic esters. It
is believed that the lone pairs of electrons on THF act as a Lewis base and
coordinate to the boron atom, freeing the boronic ester from the stationary phase
of the column.
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Table 6.1: Syntheses of Benzaldehyde Boronic Esters.a

X

CHO

Starting
Benzaldehyde

Entry

O
B O

O
O
B B
O
O
PdCl2(dppf)
KOAc DMSO
o
80 C

Time (h)

CHO

Productb
O
B

I

1

O

3
CHO

Yieldc (%)

60

CHO
68

O

Br

2

B

O

1.5

28

CHO

CHO
69

O

3

I

3

O

O
B

O

67
O

O

CHO
70

CHO
44
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Table 6.1 Continued
Starting
Benzaldehyde

Entry

Time (h)

Productb

O
I

4

3.5

O

O
B

O

87
CHO
71

CHO

45

I

5

Yieldc (%)

2.5
CHO
47

O

O
B

43
CHO
72

a

All reactions used 0.03 molar equivalents of PdCl2(dppf) catalyst, 3 molar equivalents of
potassium acetate, and 1.1 molar equivalents of bis(pinacolato)diboron in DMSO.
b
All products exhibited satisfactory spectral (1H, 13C NMR, 11B) and analytical properties.
c
Isolated Yields
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6.1.3 Attempted Synthesis of a Boronic Ester of Anabaseine
For the targeted benzylidene anabaseine derivatives containing the
potassium trifluoroborate group on the pyridine ring (66 and 67 of Table 5.3), the
required precursor for Synthetic Strategy B is the boronic ester of anabaseine, 73
in Figure 6.1. Bromoanabaseine, 27, as noted in section 4.3.4, is an unstable
molecule. Despite its instability, attempts were made to convert it to a boronic
ester. As noted in section 5.3.2, anabaseine contains an imine group with a
saturated α-carbon sensitive to strong bases. Therefore a lithium – bromide
exchange followed by addition of triisopropyl borate and then hydrolysis was not
a feasible pathway to the boronic acid. The palladium catalytic boronation
reaction successfully converted other halogenated benzylidene anabaseines to the
corresponding boronic esters (section 5.3.3). It was anticipated that this catalysis
would be successful with 27.
The reaction conditions used to generate the boronic esters of benzylidene
anabaseines in section 5.3.3 were applied to 27. The same problem was
encountered. Purification of the boronic ester was extremely difficult. The
product obtained exhibited Rf values of zero during various TLC analyses.
Column purification led to complete loss of product. A second attempt to isolate
the compound was conducted by generating of the dihydrochloride salt. After
completion of the reaction, DMSO was removed via Kügelrohr distillation.
Boiling ethyl acetate dissolved the product and excess potassium acetate was
removed by filtration. The filtrate was concentrated, diluted with isopropanol, and
treated with concentrated HCl by slow addition to generate a precipitate which
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Figure 6.1: Boronic Ester of Anabaseine and its Dihydrochloride Salt.
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was thought to be compound 74 (Figure 6.1). An analysis of the solid provided
negative results for the desired product. Since compounds 66 and 67 had already
been synthesized via Synthetic Strategy A, no further attempts were made to
synthesize compounds 73 or 74.

6.2 CONDENSATION OF ANABASEINE AND BENZALDEHYDE
BORONIC ESTERS
Having successfully converted halogenated benzaldehydes to boronic
esters via the palladium catalyzed boronation reaction, a variety of benzaldehyde
boronic esters (Table 6.1) were subjected to condensation reactions with
anabaseine dihydrochloride 40. Since benzylidene anabaseine boronic esters
readily hydrolyzed, there were concerns that the condensation products would not
survive the reaction conditions used earlier in the synthesis of the halogenated
benzylidene anabaseines (Scheme 5.3). The use of a catalytic amount of
concentrated hydrochloric acid was the primary concern. In order to prevent
hydrolysis of the boronic esters, the condensation reactions were performed
without addition of hydrochloric acid (as shown in Scheme 3.2). It was assumed
that the hydrogen chloride salt of anabaseine would be sufficient to catalyze the
reaction. To enhance this effect, a slight molar excess of anabaseine
dihydrochloride (1.1 equivalents) was used. The reaction temperature was also
increased to a gentle reflux at 80 ºC. The condensations proceeded at moderate
rates, based on TLC analyses. The benzaldehyde boronic ester 70 (Table 6.1) was
formed most efficiently with a reaction time of only two hours. All other
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benzaldehydes were allowed to stir for three days before TLC analyses confirmed
complete conversion.
Although the benzylidene anabaseine boronic esters were synthesized
utilizing a different strategy, purification remained problematic. Column
purification was not carried out on the condensation products. Upon completion
of the reaction, ethanol was evaporated under reduced pressure and the residual
solid was dissolved in water. Triethylamine was then used to convert the
dihydrochloride salt to a free base. After extraction with ethyl acetate, drying
over anhydrous magnesium sulfate, and concentration of the organic layer under
reduced pressure, the products were converted directly to potassium
trifluoroborate salts. This procedure was used for all benzaldehyde boronic esters
in Table 6.1.

6.3 CONVERSION OF BENZYLIDENE ANABASEINE BORONIC
ESTERS TO POTASSIUM TRIFLUOROBORATE SALTS
The benzylidene anabaseine boronic esters synthesized via the
condensation reactions noted in the previous section were converted to the
corresponding potassium trifluoroborate salts using the methodology discussed in
section 5.3.4. After the workup of the reaction mixture (noted in the previous
section), the residual solid was dissolved in methanol. A saturated solution of
KHF2 was then added and the mixture stirred for four hours. Removal of the
solvent was conducted under reduced pressure and then high vacuum. The
trifluoroborate salt was then dissolved in boiling acetonitrile and the excess KHF2
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removed by filtration. The filtrate was concentrated under reduced pressure and
dried under high vacuum before being washed with boiling ethyl acetate to yield
the desired product. Table 6.2 contains the results of the study.
The yields obtained using this method were slightly better than those
obtained from Synthetic Strategy A. Only entry 2 resulted in a slightly lower
yield. The overall increase in yields utilizing this method was anticipated due to
the efficiency demonstrated by the condensation reaction. When using Synthetic
Strategy A, excess potassium acetate, KHF2, palladium catalyst, and side-products
are present during purification of the potassium trifluoroborate. Synthetic
Strategy B eliminates the majority of these reagents by prior purification of the
benzaldehyde boronic esters. Only a slight excess of anabaseine, KHF2 and a
minimal amount of side-products are present during purification of the potassium
trifluoroborates with this method. This results in higher yields with fewer
impurities.

6.4 SYNTHETIC STRATEGY C
Synthetic Strategy C was outlined in Scheme 3.3. By synthesizing and
purifying the potassium trifluoroborate salt of the benzaldehyde, it was
anticipated that a condensation reaction with anabaseine dihydrochloride would
afford the benzylidene anabaseine potassium trifluoroborate salt in yields similar
to those displayed in Table 5.2. This reaction sequence was attempted using
boronic ester 70 (Table 6.2). The conversion of boronic ester 70 to its
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Table 6.2: Synthesis of Benzylidene Anabaseine Potassium Trifluoroborate
Salts via Synthetic Strategy B.a
O

B

O

BF3K

O
O B

N

2HCl

Entry

N

KHF2

1. EtOH

+
CHO

2. TEN

N

Productb

Starting Benzaldehyde
O
B

Methanol

N

O

1

BF3K

61

N

Yieldc (%)

N

CHO

N

79

N

68

O

B

BF3K

O

2

51

N
62

CHO

N

69

3

O

O
B

BF3K

O

O

80
O

N

CHO
70

O
63

116

N

Table 6.2 Continued

Entry

4

Productb

Starting Material

O

O
B

Yieldc (%)

BF3K

O

O

50
N

CHO
71

64

N

BF3K

5

O

O
B

53
N
CHO
72

65

a

N

A slight excess of anabaseine dihydrochloride were utilized in the condensation reaction. The
potassium trifluoroborate salts were synthesized using 4 molar equivalents of KHF2.
b
All products exhibited satisfactory spectral (1H, 13C NMR, 11B) and analytical properties.
c
Isolated Yields
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corresponding potassium trifluoroborate, 75, proceeded smoothly in 83% yield
following procedure noted in the previous section. However, condensation of
trifluoroborate 76 with anabaseine dihydrochloride in the absence of acid was not
successful. Only one product was observed, the hydrolyzed product, as shown in
Scheme 6.2. Apparently the hydrogen chloride cleaved the trifluoroborate
substituent, presumably forming potassium monochlorotrifluoroborate and the
hydrolyzed benzylidene anabaseine 77.

6.5 SUMMARY
Based on the five examples prepared, Synthetic Strategy B is more
efficient than Synthetic Strategy A for synthesizing potassium trifluoroborate salts
of benzylidene anabaseine. The benzaldehyde boronic esters can be purified prior
to condensation with anabaseine to eliminate the necessity of removing excess
starting materials during purification of the trifluoroborate salts. This results in a
higher yield of purer products. The syntheses of trifluoroborate salts 66 and 67
were not successful using Synthetic Strategy B due to difficulties encountered in
isolation of the boronic esters of anabaseine. Synthetic Strategy C is not a viable
pathway due to hydrolysis of the potassium trifluoroborate group in the presence
of hydrogen chloride.
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Scheme 6.2: Attempted Synthesis of a Benzylidene Anabaseine
Trifluoroborate Salt Utilizing Synthetic Strategy C.
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Chapter 7 Radiolabeling

The syntheses of a family of benzylidene anabaseine potassium
trifluoroborate salts, the precursors to the targeted radiopharmaceuticals, were
described in chapters 5 and 6. This chapter focuses on the radiolabeling of those
precursors and includes an overview of the radiolabeling reaction and its
application.

7.1 RADIOLABELING OVERVIEW
Radiolabeling of boron compounds was first developed by our group in
1978.135 Labeling was performed using trialkylborane reagents employing a
carbonylation reaction with 14CO. Hydroboration of an alkene with a
dialkylborane, monoalkylborane, or borane generated the mono-, di-, or
trialkylborane. Carbonylation was performed with 14CO in a manner paralleling
that used for carbonylations with organometallic reagents.136 Oxidation with
peroxide afforded carbon-14 labeled molecules in good yields. Carbonylation
using the monoalkylborane proved to be the most efficient method to afford the
highest yields. Equation 1 of Scheme 7.1 contains a representative example.
No-carrier-added radiohalogenations of organoborane compounds was
also first reported by our research group. Sodium iodine-125 was allowed to react
with trialkylboranes in the presence of a mild oxidizing agent such as chloramineT.137 The reaction proved to be tolerant of reactive functional groups producing
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Scheme 7.1: Radiolabeling Reactions of Organoboron Compounds.
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high yields. The procedure is carried out via the addition of sodium iodide-125 to
the desired trialkylborane, and then chloramine-T is added. Equation 2 in Scheme
7.1 contains a representative example. This methodology was also successfully
applied to arylboronic esters139 and, more recently, to organic potassium
trifluoroborate salts (Scheme 7.1).140, 141 Arylboronic acids are also readily
radiohalogenated.138 However, as noted in section 5.3.2, boronic acids are
generally prepared using aryllithium and arylmagnesium halides. These highly
reactive reagents are not compatible with radiopharmaceuticals bearing reactive
functionalities such as ketones or esters.
The reaction sequence for radiohalogenation using peracetic acid and
chloramine-T is outlined in Scheme 7.2. Chloramine-T hydrolyzes under neutral
conditions to liberate sodium hypochlorite. The sodium hypochlorite oxidizes the
halide ion to form hypoiodous or hypobromous acid, unstable compounds in
which the halogen carries a partial positive charge. Peracetic acid oxidizes halide
ions in a similar manner. The partially positive halogens then act as electophiles
in the halogenation of the trifluoroborate salts.142
Organic potassium trifluoroborate compounds are ideal precursors for
radiolabeling with iodide or bromide reagents. Due to the non-toxic nature of
boron compared to alternative organometallic precursors such as tin, radiolabeling
compounds for use in vivo PET or SPECT trials poses no threat to the health of a
patient. Short reaction times of 10 minutes or less keep possible radiation
exposure to the chemist at a minimum. The stability and subsequent long shelf life
allows the trifluoroborate precursors to be prepared and stored well in advance of
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Scheme 7.2: Reaction Sequence for Halogenation of Trifluoroborate Salts.
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(3)

(4)

the incorporation of the radioisotopes. Radiolabeling can be conducted on a nocarrier-added basis, ensuring the quantity of the labeled agent is kept below
pharmacological dosages during nuclear medicine procedures.

7.2 HALOGENATION OF BENZYLIDENE ANABASEINE
TRIFLUOROBORATE SALTS
Prior to radiolabeling, the benzylidene anabaseine trifluoroborate salts
(compounds 61 - 67) were subjected to halogenations using stable isotopes under
conditions essentially identical to those to be used in the radiolabeling
experiments. Equal molar equivalents of the trifluoroborate salt, halide ion, and
oxidant were stirred in a 50% aqueous THF solution. Both peracetic acid and
chloramine-T were used in various experimental trials. The use of peracetic acid
resulted in protonation of the pyridine and imine nitrogen’s of anabaseine, but did
not hinder the reaction. However, in these experiments, triethylamine was
required to deprotonate the product during workup. A more detailed description
can be found in Chapter 9. Table 7.1 contains the results of halogenation
experiments using peracetic acid. Table 7.2 contains the results of halogenations
using chloramine-T.
The trifluoroborate salts 61 - 65 were successfully halogenated using
peracetic acid or chloramine-T in good to excellent yields. However,
trifluoroborate salts 66 and 67 failed to produce the desired halogenated product
based on GCMS analysis. TLC analysis of the reaction mixtures using 67 and 68
as starting materials suggested the desired products had formed. Apparently, all
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Table 7.1: Halogenation of Benzylidene Anabaseine Potassium
Trifluoroborate Salts with Peracetic Acid.a
X

BF3K
-

X
Peracetic acid
THF/H2O
N

Entry

1

N

N

N

Productb

Starting Material

BF3K
N

I
N

61

N

53

N

Br

84

N
62

N

54

N

BF3K

I

O

3

N

O

100

O
63

N

N

O
2

N

BF3K

Br

O

4

N

O
63

63

N

BF3K

2

Yieldc (%)

O

81
N

N

O
56

125

N

Table 7.1 Continued

Entry

Starting Material

Productb

BF3K

I

Yieldc (%)

O

O

5

71
N

N
64

N

55

N

BF3K

Br
O

O

6

100 (81)
N

N
64

N

77

N

BF3K

I

100

7
N

N
65

N

57

N

BF3K

Br

100 (55)

8
N

N
65

N

78

a

N

All halogenations were performed using equal molar equivalents of trifluoroborate salt, peracetic
acid and halogen (NaI or NH4Br) and stirred for 30 min.
b
All products exhibited satisfactory spectral (1H, 13C NMR) and analytical properties.
c
All yields are GCMS yields except those in parentheses which are isolated yields.
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Table 7.2: Halogenation of Benzylidene Anabaseine Potassium
Trifluoroborate Salts with Chloramine-T.a
X

BF3K
-

X
Chloramine-T
THF/H2O
N

Entry

1

N

N

N

Productb

Starting Material

BF3K
N

I
N

61

N

53

N

Br

73d

N
62

N

54

N

BF3K

I

O

3

N

O

78

O
63

N

N

O
2

N

BF3K

I

O

4

70d

N

BF3K

2

Yieldc (%)

O

71

N

N
64

N

55

127

N

Table 7.2 Continued

Entry

Productb

Starting Material
BF3K

Yieldc (%)
I

5

63
N

N
65

N

57

a

N

All halogenations were performed using equal molar equivalents of trifluoroborate salt,
chloramine-T and halogen (NaI or NH4Br) and stirred for 30 min.
b
All products exhibited satisfactory spectral (1H, 13C NMR) and analytical properties.
c
All yields are GCMS yields.
d
Reaction mixture heated to 50 ºC
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products were lost during workup. Trials performed in which the reaction
mixture was immediately subjected to column chromatography also resulted in
loss of product.
The position of the trifluoroborate functionality on the pyridine ring is
presumably responsible for the loss of product. Pyridylboronic esters have been
reported to be unstable, especially when the boronic ester group is located at the
6-position.90 Although 66 and 67 are both substituted on the 5-position of the
pyridine ring, the reaction conditions apparently do not favor the isolation of the
desired product. An investigation of halogenations with pyridyl potassium
trifluoroborate salts may be of interest for future research to determine favorable
conditions for halogenation.

7.3 RADIOLABELING OF BENZYLIDENE ANABASEINE
TRIFLUOROBORATE POTASSIUM SALTS
The benzylidene anabaseine potassium trifluoroborates 63 and 65 were
chosen as starting material for radiohalogenation experiments. Both compounds
were successfully halogenated under radiolabeling conditions (Tables 7.1 and
7.2), and their structures were desirable for α7-nAChR binding. The results are
discussed in the following sections.

7.3.1 Radiolabeling with Ammonium Bromide-76
Bromine-76 is a positron emitter with a half-life of 16.2 hours. The
radiolabeling of trifluoroborates 63 and 65 with ammonium bromide-76 were
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performed with peracetic acid and chloramine-T as the oxidant to generate the
radioactive compounds 79 and 80 (Table 7.3). As noted in section 7.2, the use of
peracetic acid results in protonation of the pyridine and imine nitrogen’s of
anabaseine. The use of triethylamine, however, was not used for deprotonation
due to the hazard associated in handling radioactive isotopes. In all trials, the
trifluoroborate was first mixed with the radioisotope followed by addition of an
equal molar amount of the oxidant. The use of an equal molar amount of sodium
bromide as a carrier was included to enable multiple trials with a small amount of
the radioactive isotope. After stirring 25 min, the reaction mixtures were then
transferred directly to a Sep-pak cartridge and eluted with a predetermined solvent
system. Table 7.3 contains the radiochemical yields for the reactions.
The radiochemical yields average approximately 50% for all entries.
Considering an equal molar amount of a carrier, sodium bromide, was included,
the yields are satisfactory. Radio-TLC analyses suggest the purity is enhanced
with the use of chloramine-T in comparison to peracetic acid. This may or may
not be true due to “impurities” actually being the protonated product due to the
acidic nature of peracetic acid. Figure 7.1 contains the radio-TLC analyses of two
bromination reactions performed on 65 with different oxidants. The Rf of the
radioactivity peak on the chloramine-T trial’s TLC (Figure 7.1a) is larger than the
Rf of the major radioactivity peak on the peracetic acid trial’s TLC (Figure 7.1b).
However, the peracetic acid trial displays a small peak of radioactivity with an Rf
similar to the Rf of the major radioactive peak from the chloramin-T reaction’s
radio-TLC. The major product of the peracetic acid trial, therefore, appears to be
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Table 7.3: Halogenation of Benzylidene Anabaseine Potassium
Trifluoroborate Salts with Peracetic Acid.a
Entry

Starting Material

Productb

BF3K

76

Yieldc
(%)

Chloramine-T

40

Peracetic
Acid

65

Chloramine-T

57

Peracetic
Acid

47

Br

1
N

Oxidant

N

65

N

79

N

76

BF3K

Br

2
N

N
65

N

79

N
76

Br

BF3K

O

O

3
N

N

O
63

O
80

N

N

76

Br

BF3K

O

O

4
N

O
63

N

N

O
80

a

N

All radiobromination reactions were performed with NH476Br and equal molar equivalents of
trifluoroborate salt and oxidant. The reaction time was 25 min.
b
All products exhibited satisfactory radio-TLC analyses.
c
All yields are radiochemical yields.
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a.

b.
Figure 7.1: Radio-TLC Analyses of Radioactive Bromination Reactions. a)
Radio-TLC performed on a bromination reaction with chloramine-T as the
oxidant. b) Radio-TLC performed on a bromination reaction with peracetic
acid as the oxidant.
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the protonated compound. These results were confirmed via GCMS with trials
performed on stable isotopes.

7.3.2 Radiolabeling with Sodium Iodide-123
Sodium Iodide-123, a single photon emitter with a half life of 13.2 hours,
was used in radioiodination of trifluoroborate 63 with peracetic acid as the
oxidant to give the radioactive compound 81 (Scheme 7.3). The reaction was
successful based on radio-TLC analyses. A reaction time of 20 min resulted in a
radiochemical yield of 73%. A reaction time of 30 min resulted in a
radiochemical yield of 94%. The radiolabeled compound 81 was used in
preliminary tests for the detection of SCLC via SPECT imaging. The results of
the SPECT imaging are discussed in the next section.

7.3.3 Preliminary SPECT Results
Using a hamster lung tumor model developed by Schuller’s group, 143
iodine-123 labeled benzylidene anabaseine 81 was synthesized and used in a
preliminary investigation involving the detection of SCLC. Two hamsters, a
control hamster, and a tumor bearing hamster were injected with iodine-123
labeled benzylidene anabaseine 81. After 20 minutes, the hamsters were
sacrificed and a SPECT image was acquired. Figure 7.2 contains the images.
The image of the control hamster reveals uptake at the injection site, the
bladder, and the intestines, but no uptake in the lungs. The tumor bearing hamster
displays a significant uptake of the radiolabeled agent at the tumor site in the
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BF3K

I
O

O
123

Na I
Peracetic Acid
N

O

THF/H2O

N

O

N

N

63

81

Scheme 7.3: Radioiodination of Potassium Trifluoroborate 63.
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Figure 7.2: SPECT Image of a Tumor Bearing Hamster.
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lungs.

7.4 Summary
Benzylidene anabaseine potassium trifluoroborate salts can be
successfully halogenated using methods previously developed by our research
group. Chloramine-T or peracetic acid can be used as the oxidant, but
chloramine-T produces a free base product whereas peracetic acid produces a
protonated product. Successful radiolabeling experiments using bromine-76 and
iodine-123 were performed. A preliminary imaging experiment focused on SCLC
detection was performed with radiolabeled benzylidene anabaseine 81 using
SPECT. Compound 81 displayed successful uptake at a lung tumor site.
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Chapter 8 Conclusions and Future Work
8.1 CONCLUSIONS
New and convenient syntheses of anabaseine and its benzylidene
derivatives ware developed. The synthesis of a family of benzylidene anabaseine
potassium trifluoroborate salts was achieved by utilization of the newly developed
route to anabaseine. Halogenations of the trifluoroborate salts were successful in
all but two cases in which the trifluoroborate was located on the pyridine ring.
Radiolabeling of compounds 63 and 65 with iodine-123 and bromine-76 was
successful. Preliminary SPECT images obtained from the use of compound 81
suggest radiolabeled derivatives of benzylidene anabaseines have potential use in
the early detection of SCLC.

8.2 FUTURE WORK
The overall yields of the syntheses of anabaseine and the corresponding
benzylidene anabaseines could be improved with additional effort focused on the
conversion of the condensation product to the halide. An investigation of the rate
of addition of the acid and the reaction times should lead to improved conditions
and higher yields. With the high yields of all other reactions in the sequence, the
overall yield would be significantly improved.
Nitrogen heterocycles containing potassium trifluoroborate salts have not
been investigated thoroughly. The difficulty noted in halogenation of compounds
66 and 67 suggests that halogenation of salts bearing trifluoroborate functionality
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on a pyridine ring should be investigated. It would be beneficial for medicinal
chemists to have this type of reaction available as many biologically active
compounds contain nitrogen heterocyclic rings.
Future work involving the family of benzylidene anabaseine
trifluoroborate salts should focus on in vivo evaluations of healthy anesthetized
hamsters to determine which derivatives have the least non-specific uptake at the
projected tumor location. Once the derivative containing the least non-specific
uptake is determined, tumor bearing hamsters should be investigated further.
After injection and imaging, the health and behavior of the hamsters should be
monitored to determine the toxicology of the targeted compounds.
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Chapter 9 Experimental

9.1 GENERAL CONSIDERATIONS
Nuclear magnetic resonance (NMR) spectra for proton (1H) and carbon
(13C) were acquired using one of three spectrometers, a Varian Mercury 300
operating at 300.09 (1H) and 75.46 MHz (13C), a Bruker WP250 at 250.13 (1H)
and 62.89 MHz (13C), or a Bruker Avance 400 at 400.04 (1H) and 100.59 MHz
(13C). Chemical shifts were referenced in parts per million (ppm) to either
tetramethylsilane or utilizing the chemical shifts of the deuterated solvents.
Boron (11B) NMR spectra were acquired from a Bruker Avance 400 spectrometer
at 128.38 MHz. Chemical shifts for 11B spectra were referenced to an external
standard of boron trifluoride etherate. Fluorine (19F) NMR specrtra were acquired
on a Varian Mercury 300 spectrometer and 19F chemical shifts were referenced to
an external standard of 5% fluoroform in chloroform-d. Coupling constants (J
values) are reported in Hertz (Hz), and spin multiplicities are indicated by the
following symbols: s (singlet), d (doublet), dd (doublet of doublets), dt (doublet of
triplets), t (triplet), q (quartet), and m (multiplet). Thin layer chromatography
(TLC) was performed on Analtech 250 micron silica gel glass TLC plates with
compounds being located on the plates using ultraviolet light (254 nm) or an
iodine chamber. Elemental analyses were performed by Atlantic Microlabs Inc.,
Norcross, GA. Mass spectral analyses were acquired on a VG Quattro II
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electrospray mass spectrometer. Melting points were acquired on a ThomasHoover melting point apparatus and are uncorrected.
All commercial reagents were purchased from Aldrich Chemical Co. or
from Acros Organics and used as received without further purification. Solvents
were reagent grade and used as purchased from Fisher Chemical Co. except
tetrahydrofuran which was distilled from sodium benzophenone ketyl.
Column chromatography was performed on silica gel purchased from
Bodman Chemical. The silica gel was 60 Å and 230-400 mesh. The pH of
solutions was determined using Whatman pH Indicator paper.
All glassware was cleaned in a base bath, oven dried, and cooled under an
inert gas (argon or nitrogen) prior to use.

9.2 EXPERIMENTAL PROCEDURES FOR THE SYNTHESIS OF
ANABASEINE AND 5’-BROMOANABASEINE

9.2.1 Synthesis of Ethyl 5-bromonicotinate, 28.144
In a 100mL round bottom flask equipped with a stir bar and reflux
condenser, 5-bromonicotinic acid (5.00 g, 24.8 mmol) was placed along with
absolute ethanol (50 mL). The solution was heated to 80 ºC. Sulfuric Acid (2.5
mL) was then added and the solution was allowed to stir for 13 hours at 80 ºC.
The excess ethyl alcohol was removed under reduced pressure. The concentrated
mixture was transferred to a separatory funnel; water was added (100 mL), and
the product extracted with ethyl acetate (2 x 100mL). The combined organic
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layers were washed with a 10% sodium bicarbonate solution (3 x 100ml) or until
gas formation subsided and then washed with brine (100 ml). The organic layer
was dried over anhydrous magnesium sulfate, filtered and the solvent removed
under reduced pressure. The resultant solid was dissolved in a minimal amount of
ethyl acetate and purified via column chromatography (SiO2; 8:1 = hexanes:
EtOAc) to yield 5.06 g (89%) of a white solid. Mp = 41-42 ºC. 1H NMR
(CDCl3): δ 1.42 (t, 3H), 4.43 (q, 2H), 8.43 (t, 1H), 8.84 (d, J = 2 Hz, 1H), and
9.129 (d, J = 1.5, 1H); 13C NMR (CDCl3) δ 14.2, 61.8, 120.5, 127.6, 139.4, 148.8,
154.4, and 163.9.

9.2.2 General Synthesis of Compounds 24, 25, 36, and 37.
In a 500 mL 3-necked flask round bottom flask, δ-valerolactone (2.10 g,
21.0 mmol, 1 eq) was dissolved in THF (150 mL). Sodium hydride (1.33 g, 33.0
mmol, 1.5 eq; 60% suspension in mineral oil) was added at 0 ºC and the
suspension stirred for 15 min and then for 1 hr at room temperature. Ethyl
nicotinate or ethyl-5-bromonicotinate (11.7 mmol, 0.56 eq) in THF (10 mL) was
slowly added at 0 ºC. The reaction mixture was brought to room temperature and
stirred for 12 hr under an inert atmosphere in the absence of light. The solvent
was removed under reduced pressure to obtain a yellowish solid, which was
suspended in dry ether. The solid was isolated by filtration and added to a 100
mL round bottom flask. Aqueous HBr (48%, 30 mL) or aqueous HCl (37%,
30ml) was then added slowly and the mixture heated to 110 ºC for approximately
30 min. Lithium bromide (2.04 g, 23 mmol, 1.1 eq) or lithium chloride (1.00g,
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23.0 mmol, 1.1 eq) was then added slowly and allowed to reflux for 1 hour. The
dark brown solution was brought to pH 8 using Na2CO3 and then extracted with
EtOAc (2 x 100 mL). The combined organic extracts were dried over anhydrous
Na2SO4, filtered, and the solvent removed under reduced pressure. The resulting
mixture was then purified by flash chromatography as described in the analytical
section for each specific compound.

9.2.3 Analytical Data for Compounds 24, 25, 36, and 37.

9.2.3.1 5-Chloro-1-pyridin-3-yl-pentan-1-one, 24. 102
The synthesis was conducted as described in the general procedure using
δ-valerolactone (3.45 g, 34.5 mmol, 1 eq), ethyl nicotinate (2.92g, 19.3 mmol,
0.56 eq), 30 mL HBr (37%), and lithium chloride (1.86g, 43.9 mmol, 1.1 eq). The
brown oil was purified by flash chromatography (SiO2; 7:2 = hexane: EtOAc) to
yield 2.70 g (51%) of a light brown oil that was unstable in air. 1H NMR
(CDCl3): δ 1.81-1.98 (m, 4H), 3.05 (t, 2H), 3.60 (t, 2H), 7.44 (dd, J1 = 7.75 Hz, J2
= 4.75 Hz, 1H), 8.25 (dt, J = 7.75 Hz, 1H), 8.80 (dd, J1 = 4.75 Hz, J2 = 1.5, 1H),
and 9.17 (d, J = 1.4 Hz, 1H).

13

C NMR (CDCl3): δ 21.1, 31.8, 37.8, 44.5, 123.7,

132.0, 135.3, 149.5, 153.5, and 198.3.

9.2.3.2 5-Bromo-1-pyridin-3-yl-pentan-1-one, 25.
The synthesis was conducted as described in the general procedure using
δ-valerolactone (3.45 g, 34.5 mmol, 1 eq), ethyl nicotinate (2.92g, 19.3 mmol,
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0.56 eq), 30 mL HBr (37%), and lithium bromide (3.82g, 43.9 mmol, 1.1 eq).
The brown oil was purified by flash chromatography (SiO2; 7:2 = hexane: EtOAc)
to yield 2.70 g (51%) of a light brown oil that was unstable in air. 1H NMR
(CDCl3): δ 1.81-2.11 (m, 4H), 3.06 (t, 2H), 3.47 (t, 2H), 7.45 (dd, J1 = 7.79 Hz, J2
= 4.83 Hz, 1H), 8.24 (dt, J = 7.88 Hz, 1H), 8.79 (dd, J1 = 4.47 Hz, J2 = 1.06 Hz
1H), and 9.17 (d, J = 1.4 Hz, 1H).
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C NMR (CDCl3): δ 22.2, 31.8, 33.1, 37.5,

123.5, 131.8, 135.1, 149.3, 153.3, and 198.1.

9.2.3.3 5-Bromo-3-(5-bromo-1-pentanon-1-yl)pyridine, 36.
The synthesis was conducted as described in the general procedure using
δ-valerolactone (2.1 g, 21.0 mmol, 1eq), ethyl-5-bromo nicotinate (2.7 g, 11.7
mmol, 0.56 eq), 20 mL HBr (48%), and lithium bromide (2.0 g, 23.0 mmol, 1.1
eq). The brown solid was purified by dissolving it in a minimal amount of
CH2Cl2 and performing flash chromatography (SiO2; 3:1 = hexane: EtOAc) to
yield 1.98 g (53%) of a tan solid. Mp = 74-75 °C. 1H NMR (CDCl3): δ 1.69-2.01
(m, 4H), 3.03 (t, 2H), 3.46 (t, 2H), 8.36 (t, 1H), 8.85 (d, J = 2.25 Hz, 1H), and
9.07 (d, J = 1.5 Hz, 1H).
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C NMR (CDCl3): δ 22.2, 31.7, 33.0, 37.9, 121.3,

133.1, 137.6, 147.3, 154.4, and 196.9. Anal. Calcd. for C10H11Br2NO: C, 37.42;
H, 3.45; N, 4.36. Found: C, 37.66; H, 3.44; N, 4.42.

9.2.3.4 5-Bromo-3-(5-chloro-1-pentanon-1-yl)pyridine, 37.
The synthesis was conducted as described in the general procedure using
δ-valerolactone (2.1 g, 21.0 mmol, 1eq), ethyl-5-bromo nicotinate (2.7 g, 11.7
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mmol, 0.56 eq), 20 mL HCl (37%), and lithium chloride (1.0 g, 23.4 mmol, 1.1
eq). The brown solid was purified by dissolving it in a minimal amount of
CH2Cl2 and performing flash chromatography (SiO2; 7:2 = hexane: EtOAc) to
yield 1.74 g (54%) of a white solid. Mp = 68-69 °C. 1H NMR (CDCl3): δ 1.831.98 (m, 4H), 3.03 (t, 2H), 3.60 (t, 2H), 8.36 (t, 1H), 8.85 (d, J = 2.25 Hz, 1H),
and 9.07 (d, J = 1.75 Hz, 1H).
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C NMR (CDCl3): δ 21.0, 31.7, 38.1, 44.5, 121.3,

133.2, 137.8, 147.3, 154.5, and 196.9. Anal. Calcd. for C10H11BrClNO: C,
43.43; H, 4.01; N, 5.06. Found: C, 43.71; H, 4.02; N, 4.93.

9.2.4 Synthesis of 5-Azido-1-pyridin-3-yl-pentan-1-one, 38.
In a 50 mL round bottom flask equipped with a pressure regulated addition
funnel, 18-crown-6 (70 mg, 0.26 mmol) and sodium azide (1.00 g, 15.3 mmol)
were added. The apparatus was placed on high vacuum for 3 hours and backfilled
with argon. A mixture of 5-chloro-1-pyridin-3-yl-pentan-1-one, 24 (2.52 g, 12.7
mmol), in DMF (40 mL) was added to the addition funnel and then slowly added
to the mixture at 80 °C over a 1.5 hr period. The funnel was rinsed with DMF (5
mL) and the mixture allowed to stir for 15 hours at 80 °C. After cooling to room
temperature, the mixture was quenched with water (75 mL) and extracted with
EtOAc (2 x 75 mL). The combined organic extracts were washed with water (3 x
75 mL), dried over anhydrous MgSO4, filtered, and concentrated under reduced
pressure to obtain a brown oil. The product was purified via flash
chromatography (SiO2; 2:1 = hexanes: EtOAc) to yield 2.49 g (96%) of a clear
liquid. 1H NMR (CDCl3): δ 1.65–1.76 (m, 2H), 1.81–1.93 (m, 2H), 3.05 (t, 2H),
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3.36 (t 2H), 7.45 (dd, J1 = 7.85 Hz, J2 = 4.89 Hz 1H), 8.24 (dt, J = 7.98 1H), 8.79
(dd, J1 = 4.76 Hz, J2 = 1.45 Hz, 1H) and 9.16 (s, 1H).
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C NMR (CDCl3): δ 20.9,

28.3, 38.1, 51.2, 123.6, 132.0, 135.2, 149.5, 153.5, and 198.2. Anal. Calcd. for
C10H12N4O: C, 58.81; H, 5.92; N, 27.43. Found: C, 59.34; H, 5.92; N, 26.97.

9.2.5 Synthesis of 5-Bromo-3-(5-azido-1-pentanone-1-yl)pyridine, 39.
In a 50 mL round bottom flask equipped with a pressure regulated addition
funnel, 18-crown-6 (50 mg, 0.2 mmol) and sodium azide (292 mg, 4.50 mmol)
were added. The apparatus was placed on high vacuum for 3 hours and backfilled
with argon. A mixture of 5-bromo-3-(5-bromo-1-pentanon-1-yl)pyridine (1.20 g,
3.70 mmol) in DMF (20 mL) was added to the addition funnel and then slowly
added to the mixture at 80 °C over a 1.5 hr period. The funnel was rinsed with
DMF (5 mL) and the mixture was allowed to stir for 15 hours at 80 °C. After
cooling to room temperature, the mixture was quenched with water (50 mL) and
extracted with EtOAc (2 x 50 mL). The combined extracts were washed with
water (3 x 75 mL), dried over anhydrous MgSO4, filtered, and concentrated under
reduced pressure to obtain a brown oil. The product was purified via flash
chromatography (SiO2; 3:1 = hexanes: EtOAc) to yield 1.0 g (96%) of a white
solid. A similar yield (92%) was obtained if 5-bromo-3-(5-chloro-1-pentanon-1yl)pyridine was used. Mp = 38–39 °C. 1H NMR (CDCl3): δ 1.64–1.75 (m, 2H),
1.80–1.92 (m. 2H), 3.028 (t, 2H), 3.36 (t 2H), 8.36 (t, 1H), 8.85 (d, J = 2.25 Hz,
1H), and 9.06 (d, J = 1.75 Hz, 1H).
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C NMR (CDCl3): δ 20.8, 28.3, 38.3, 51.2,
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121.4, 133.2, 137.8, 147.3, 154.5, and 196.9. Anal. Calcd. for C10H11BrN4O: C,
42.42; H, 3.92; N, 19.79. Found: C, 42.92; H, 3.93; N, 19.87.

9.2.6 Synthesis of Anabaseine, 1.96, 97, 98, 99, 100, 101,102
In a 100mL round bottom flask, 5-azido-1-pyridin-3-yl-pentan-1-one (2.49 g, 12.2
mmol) and triphenylphosphine (3.52 g, 13.4 mmol) were added. A mixture of
THF (55 mL) and water (200 µL) was then added and the mixture stirred at room
temperature for 12 hours. The solvent was removed under reduced pressure to
give a yellow solid that was dissolved in a minimal amount of CH2Cl2 and added
directly to a column. Flash chromatography was performed (SiO2; EtOAc as
eluent) to yield 1.78 g (96%) of a clear liquid that was very sensitive to air. 1H
NMR (CDCl3): δ 1.66-1.74 (m, 2H), 1.82-1.91 (m, 2H), 2.59-2.66 (m, 2H), 3.823.88 (m, 2H), 7.31 (dd, J1 = 8.00 Hz, J2 = 4.62 Hz 1H), 8.10 (dt, J = 8.06 Hz, 1H),
8.61 (dd J1 = 4.74 Hz, J2 = 1.61 Hz 1H) and 8.95 (d, J = 2.01 Hz, 1H).
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C NMR

(CDCl3): δ 19.4, 21.7, 26.9, 49.9, 123.1, 133.3, 135.3, 147.5, 150.4, and 163.6.

9.2.7 Synthesis of 5’-Bromoanabaseine, 27.
In a 100mL round bottom flask, 5-bromo-3-(5-azido-1-pentanone-1yl)pyridine (1.01 g, 3.50 mmol) and triphenylphosphine (1.02 g, 3.9 mmol) were
added. A mixture of THF (25 mL) and water (60 µL) was then added and the
mixture stirred at room temperature for 12 hours. The solvent was removed under
reduced pressure to give a yellow solid that was dissolved in a minimal amount of
CH2Cl2 and added directly to a column. Flash chromatography was performed
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(SiO2; 3:1, 2:1, 1:1 = hexanes: EtOAc) to yield 846 mg (96%) of an air sensitive
white solid. Mp = 38–39 °C. 1H NMR (CDCl3): δ 1.66–1.74 (m, 2H), 1.81–1.90
(m, 2H), 2.57-2.63 (m, 2H), 3.83-3.89 (m, 2H), 8.26 (t, 1H), 8.67 (d, J = 1.75 Hz,
1H), and 8.85 (d, J = 1.25 Hz, 1H).

13

C NMR (CDCl3): δ 19.3, 21.6, 26.9, 50.1,

120.6, 136.0, 136.7, 145.5, 151.4, and 162.4. Anal. Calcd. for C10H11BrN2: C,
50.23; H, 4.64; N, 11.63. Found: C, 50.35; H, 4.42; N, 11.63.

9.2.8 Synthesis of Anabaseine Dihydrochloride, 40.
In a 100 mL round bottom flask, anabaseine (1.76 g, 11.0 mmol) was
dissolved in isopropyl alcohol (30 mL). Concentrated HCl (37%) was added
dropwise until a precipitate formed. The mixture was allowed to stir for 30 min at
room temperature. Ethyl acetate (20 mL) was then added to the mixture to further
precipitate the salt. The solid was filtered and rinsed with ethyl acetate. The
filtrate was concentrated under reduced pressure and diluted with more ethyl
acetate to induce further precipitation. The solid was again filtered and rinsed
with ethyl acetate to yield a combined total of 2.35 g (92%) of a white solid. Mp
= 152-154 °C. 1H NMR (DMSO-d6): δ 1.62-1.75 (m, 4H), 2.79-2.89 (m, 2H),
3.22 (t, 2H), 5.89 (s, 1H) 8.01 (dd, J1 = 7.84 Hz, J2 = 5.49 Hz 1H), 8.23 (s, 1H),
8.73 (d, J = 7.92 Hz, 1H), 8.98 (d, J = 5.03 Hz, 1H) and 9.30 (s, 1H).
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C NMR

(DMSO-d6): δ 19.9, 26.2, 37.8, 38.3, 126.1, 133.5, 140.9, 144.4, 147.7, and
197.4.
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9.2.9 Synthesis of 5’-Bromoanabaseine Dihydrochloride, 41.
In a 100 mL flask, 5’-bromoanabaseine (814 mg, 3.40 mmol) was
dissolved in isopropyl alcohol (20mL). Concentrated HCl (37%) was added
dropwise until a precipitate formed. The mixture was allowed to stir for 30 min at
room temperature. Ethyl acetate (20 mL) was then added to the mixture to further
precipitate the salt. The solid was filtered and rinsed with ethyl acetate. The
filtrate was concentrated under reduced pressure and diluted with more ethyl
acetate to induce further precipitation. The solid was again filtered and rinsed
with ethyl acetate to yield a combined total of 955 mg (90%) of a tan solid. Mp =
157-158 °C. 1H NMR (DMSO-d6): δ 1.64-1.71 (m, 4H), 2.78-2.86 (m, 2H),
3.166 (t, 2H), 8.17 (s, 1H), 8.53 (t, 1H), 8.71 (s, 1H), 8.97 (d, J = 2.10 Hz), and
9.11 (d, J = 1.64 Hz).
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C NMR (DMSO-d6): δ 20.1, 26.3, 37.9, 38.4, 120.6,

133.4, 137.9, 147.4, 153.7, and 198.2.

9.3 EXPERIMENTAL PROCEDURES FOR THE SYNTHESIS OF
HALOGENATED BENZALDEHYDES

9.3.1 Synthesis of 5-Iodo-2,4-dimethyoxybenzaldehyde, 44.145
In a 100 mL flask, 2,4-dimethoxybenzaldehyde (1.50 g, 9.03 mmol) was
dissolved in methylene chloride (30 mL). Iodine monochloride (2.05 g, 12.6
mmol) was then added to the mixture followed by acetic acid (630 µL). The
mixture was allowed to stir overnight (12 hours) at room temperature. The
mixture was then diluted with methylene chloride (20 mL) and washed with a
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saturated solution of sodium thiosulfate (2 x 50 mL) and then water (100mL).
The organic layer was dried over anhydrous magnesium sulfate, filtered and
concentrated under reduced pressure. The solid was dissolved in a minimal
amount of methylene chloride and purified via flash chromatography (SiO2; 5:3 =
hexanes: EtOAc) to yield 2.42 g (92%) of a white solid. Mp = 170-171 °C. 1H
NMR (CDCl3): δ 3.94 (s, 3H), 3.96 (s, 3H), 6.38 (s, 1H), 8.19 (s, 1H), and 10.18
(s, 1H).
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C NMR (CDCl3): δ 55.9, 56.6, 75.6, 94.8, 120.4, 139.2, 163.8, 164.0,

and 186.9.

9.3.2 Synthesis of 3-Iodo-4-methoxybenzaldehyde, 45.146
In a 50 mL round bottom flask, p-anisaldehyde (1.00g, 7.30 mmol) was
added to methylene chloride (20 mL). Iodine monochloride (1.19 g, 7.30 mmol)
was then added followed by acetic acid (0.4 mL). The mixture was allowed to stir
at room temperature overnight. The mixture was diluted with methylene chloride
(30 ml) and washed with sodium thiosulfate (2 x 50 mL) and then water (50 mL).
The organic layer was dried over anhydrous magnesium sulfate, filtered, and
concentrated under reduced pressure. The remaining mixture was passed through
a short column (SiO2; 5:1 = hexanes: EtOAc) to give a mixture of p-anisaldehyde
as a liquid and the desired product as a solid. The mixture was suspended in
hexanes, filtered and rinsed with hexanes to yield 700 mg (49%) of a white solid.
Mp = 102-104 °C. 1H NMR (CDCl3): δ 3.98 (s, 3H), 6.93 (d, J = 8.45 Hz, 1H),
7.85 (dd, J1 = 8.47 Hz, J2 = 2.02 Hz, 1H), 8.30 (d, J = 1.97), and 9.82 (s, 1H).
NMR (CDCl3): δ 56.7, 86.4, 110.5, 131.4, 132.0, 141.0, 162.7, and 189.3.
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9.3.3 Synthesis of 5-Bromo-2,4-dimethyoxybenzaldehyde, 46.147
In a 100 mL round bottom flask, 2,4-dimethoxybenzaldehyde (1.20 g, 7.22
mmol) was dissolved in dichloroethane (50 mL). In a separate 50 mL round
bottom flask, sodium perborate tetrahydrate (1.54 g, 10 mmol) and HBr (48%,
1.38 mL, 12.0 mmol) were carefully mixed by slow addition of the HBr while
stirring. The HBr - sodium perborate tetrahydrate mixture was then immediately
transferred to the benzaldehyde mixture via pipette and heated to 70 °C for four
hours. Another mixture of sodium perborate tetrahydrate and HBr (48%) as
described above was then transferred and the mixture continued to stir for another
8 hours (12 hours total) at 70 °C. The mixture was then quenched with water
(100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic
layers were washed with a 10% sodium bicarbonate solution (3 x 100 mL) and
again with water (2 x 100 mL). The organic layer was dried over anhydrous
magnesium sulfate, filtered, and concentrated under reduced pressure to yield
1.69 g (95%) of a tan solid that was used without further purification. Mp = 130131 °C. 1H NMR (CDCl3): δ 3.95 (s, 3H), 3.98 (s, 3H), 6.45 (s, 1H), 7.98 (s, 1H),
and 10.22 (s, 1H).

13

C NMR (CDCl3): δ 55.9, 56.5, 95.5, 103.4, 119.3, 132.8,

161.6, 163.0, and 187.0.

9.3.4 Synthesis of 5-Iodo-2,4-dimethylbenzaldehyde, 47.116
The five step synthesis is outlined in the following sections.
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9.3.4.1 Synthesis of 2,4-Dimethylbenzoic Acid Methyl Ester, 49.
In a 100 mL round bottom flask, 2,4-dimethylbenzoic acid (10 g, 66.6
mmol), methanol (50 mL), and concentrated sulfuric acid were mixed. A reflux
condenser equipped with a drying tube was attached to the flask and the mixture
was refluxed at 65 °C for approximately 4 hours. The methanol was then
removed under reduced pressure. The product was extracted into ether (100mL)
and washed with saturated aqueous sodium bicarbonate (2 x 50 mL) and water (3
x 100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered,
and concentrated to obtain 10.1 g (93%) of a clear liquid that was used in the next
step without further purification. 1H NMR (CDCl3): δ 2.34 (s, 3H), 2.57 (s, 3H),
3.86 (s, 3H), 7.03 (d, J = 7.5 Hz, 1H), 7.05 (s, 1H), and 7.82 (d, J = 7.5 Hz, 1H).
13

C NMR (CDCl3): δ 21.3, 21.6, 51.6, 126.4, 126.6, 130.7, 132.5, 140.3, 142.4,

and 168.0.

9.3.4.2 Synthesis of 2,4-Dimethylbenzyl Alcohol, 50.
In a 250 mL flask, 2,4-dimethylbenzoic acid methyl ester, 49 (5.00 g, 30.5
mmol), was dissolved in THF (70 mL). The mixture was cooled to 0 °C, lithium
aluminum hydride (1.27 g, 33.5 mmol) was added rapidly, and the flask was
immediately purged with nitrogen. The mixture was allowed warm to room
temperature over a 15 min period and allowed to stir for 19 hours. The mixture
was then cooled to 0 °C and saturated aqueous sodium sulfate was added slowly
until the solution formed a white cake of solid. The solid was filtered and rinsed
with ether. The filtrate was concentrated to obtain 4.00 g (98%) of a yellow tinted
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liquid that was used in the next step without further purification. 1H NMR
(CDCl3): δ 1.71 (s, 1H), 2.31 (s, 3H), 2.32 (s, 3H), 4.63 (s, 2H), 7.00 (s, 2H), and
7.20 (d, J = 8.1 Hz, 1H).

13

C NMR (CDCl3): δ 18.5, 21.0, 63.4, 126.6, 127.8,

131.2, 135.7, 136.1, and 137.5.

9.3.4.3 Synthesis of 2,4-Dimethylbenzyl Acetate, 51.
In a 100 mL round bottom flask, 2, 4-dimethylbenzyl alcohol, 50 (3.92 g,
28.8 mmol), was mixed with acetic anhydride (20 mL) and pyridine (3 mL). The
mixture was allowed to sir 15 hours at room temperature, then poured into an
equal volume of crushed ice and extracted with ether (2 x 100 mL). The
combined organic layers were washed sequentially with 1N aqueous HCl (2 x 50
mL), water (100 mL), and brine (100 mL). The solution was dried over
anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The
liquid was purified via flash chromatography (SiO2; 10:1 = hexanes: EtOAc) to
yield 4.85 g (95%) of a clear liquid. 1H NMR (CDCl3): δ 2.08 (s, 3H), 2.32 (s,
6H), 5.08 (s, 2H), 7.00 (d, J = 8.70 Hz, 1H), 7.02 (s, 1H), and 7.21 (d, J = 8.70)
Hz.

13

C NMR (CDCl3): δ 18.8, 20.9, 21.1, 64.6, 126.6, 129.6, 130.9, 131.2,

137.0, 138.4, and 170.9.

9.3.4.4 Synthesis of 5-Iodo-2,4-dimethyl-benzyl Chloride, 52.
In a 250 mL round bottom flask, 2,4-dimethylbenzyl acetate, 51 (5.44 g,
30.5 mmol), was mixed with methylene chloride (50 mL), acetic acid (2.78 mL),
and iodine monochloride (5.95 g, 36.6 mmol). The reaction stirred for 15 hours at
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room temperature. The mixture was then washed with a saturated aqueous
sodium thiosulfate solution (2 x 100mL) and water (100mL). The organic layer
was dried over anhydrous sodium sulfate, filtered, and concentrated under
reduced pressure. The clear liquid was purified by flash chromatography (SiO2;
8: 1 = petroleum ether: EtOAc) to yield 4.1 g (48%) of a white solid. Mp = 49-51
°C. 1H NMR (CDCl3): δ 2.31 (s, 3H), 2.38 (s, 3H), 4.50 (s, 2H), 7.07 (s, 1H), and
7.72 (s, 1H).

13

C NMR (CDCl3): δ 18.3, 27.5, 43.5, 97.2, 132.0, 134.9, 137.2,

139.7, and 142.1. HRMS for C9H10ICl. 279.9506, Calcd. 279.9516.

9.3.4.5 Synthesis of 5-Iodo-2,4-dimethyl-benzaldehyde, 47.
In a 50 mL round bottom flask, 2,4-dimethyl-5-iodobenzyl chloride, 52
(1.0 g, 3.5 mmol), was mixed with 50% aqueous acetic acid (7 mL) and
hexamethylenetetramine (1.0 g, 7.1 mmol). The mixture was heated to reflux at
95-100 °C for 2 hours and then cooled to room temperature. Concentrated
aqueous HCl (3 mL) was then added and the mixture was brought to reflux for
approximately 30 min. After cooling to room temperature, the product was
extracted into ether (3 x 50 mL), washed sequentially with water (2 x 50 mL),
10% aqueous sodium carbonate solution (2 x 50 mL), and then brine (50 mL).
The organic layer was dried over anhydrous sodium sulfate, filtered, and
concentrated under reduced pressure. The crude product was purified via flash
chromatography (SiO2; 30: 1 = petroleum ether: EtOAc) to yield 600 mg (65%) of
a white solid. Mp = 61-62 °C. 1H NMR (CDCl3): δ 2.44 (s, 3H), 2.57 (s, 3H),
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7.13 (s, 1H), 8.16 (s, 1H), and 10.12 (s, 1H).

13

C NMR (CDCl3): δ 19.0, 28.2,

97.4, 133.1, 133.6, 140.3, 142.3, 147.7, and 190.7.

9.4 EXPERIMENTAL PROCEDURES FOR THE SYNTHESIS OF
HALOGENATED BENZYLIDENE ANABASEINE DERIVATIVES

9.4.1 General Procedure for the Synthesis of Halogenated Benzylidene
Anabaseine Derivatives
In a 100 mL round bottom flask, anabaseine dihydrochloride or 5’bromoanabaseine dihydrochloride (1 eq) was mixed with the specified
benzaldehyde (1.1-2 eq) in ethanol and concentrated hydrochloric acid (3 drops).
The mixture was heated to 70 °C for three days. Ethanol was removed under
reduced pressure and the yellow solid was dissolved in water. Triethylamine (1-2
mL) was added dropwise and the mixture was allowed to stir for 10 min. The
product was then extracted with ethyl acetate (2 x 50 mL). The organic layer was
dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced
pressure. The resulting mixture was purified via flash chromatography as
specified in the analytical section for each specific compound. Upon
concentration of the fractions, remaining solvent must be removed under high
vacuum with heat.
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9.4.2 Analytical Data of Halogenated Benzylidene Anabaseine Derivatives

9.4.2.1 3-(3-Iodobenzylidene)-3,4,5,6-tetrahydro-[2,3']bipyridine, 53.
Anabaseine dihydrochloride (167 mg, 0.72 mmol) and miodobenzaldehyde (200 mg, 0.860 mmol) were mixed in ethanol (7 mL) and
subjected to the general procedure. The resulting mixture was purified via flash
chromatography (SiO2; 10: 1, 5:1 = CH2Cl2: isopropyl alcohol) to yield 207 mg
(92%) of a yellow solid. Mp = 39-40 °C. 1H NMR (CDCl3): δ 1.83 (m, 2H), 2.76
(m, 2H), 3.89 (t, 2H), 6.55 (s, 1H), 7.09 (t, 1H), 7.25 (d, J = 7.94 Hz), 7.33 (dd, J1
= 4.91 Hz, J2 = 7.72 Hz, 1H), 7.62 (d, J = 8.17 Hz, 1H), 7.63 (s, 1H), 7.81 (dt, J =
7.81 Hz, 1H), 8.64 (dd, J1 = 1.46 Hz, J2 = 4.83 Hz, 1H), and 8.73 (d, J = 1.75 Hz,
1H).

13

C NMR (CDCl3): δ 22.3, 25.6, 50.4, 94.2, 123.0, 126.5, 129.9, 132.9,

133.9, 135.9, 136.2, 136.8, 137.9, 138.1, 149.8, and 166.6. Anal. Calcd. for
C17H15N2I: C, 54.56; H, 4.04; N, 7.49. Found: C, 54.51; H, 4.07; N, 7.36.

9.4.2.2 3-(4-Bromobenzylidene)-3,4,5,6-tetrahydro-[2,3']bipyridine, 54.
Anabaseine dihydrochloride (210 mg, 0.900 mmol) and pbromobenzaldehyde (200 mg, 1.08 mmol) were mixed in ethanol (7 mL) and
subjected to the general procedure. The resulting mixture was purified via flash
chromatography (SiO2; 5: 1 = EtOAc: methanol) to yield 262 mg (89%) of a
yellow solid. Mp = 105-106 °C. 1H NMR (CDCl3): δ 1.83 (m, 2H), 2.79 (m,
2H), 3.88 (t, 2H), 6.57 (s, 1H), 7.15 (d, J = 8.44 Hz, 2H), 7.33 (dd, J1 = 7.76 Hz,
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J2 = 4.86 Hz, 1H), 7.48 (d, J = 8.45 Hz, 2H), 7.62 (dt, J = 7.83 Hz, 1H), 8.64 (dd,
J1 = 4.79 Hz, J2 = 1.41 Hz), and 8.74 (d, J = 1.62 Hz, 1H).

13

C NMR (CDCl3): δ

22.3, 25.7, 50.3, 122.2, 123.0, 130.9, 131.5, 132.4, 134.3, 134.6, 135.9, 136.2,
149.7, and 166.7. Anal. Calcd. for C17H15N2Br: C, 62.40; H, 4.62; N, 8.56.
Found: C, 62.08; H, 4.64; N, 8.38.

9.4.2.3 3-(5-Iodo-2,4-dimethoxybenzylidene)-3,4,5,6-tetrahydro
[2,3']bipyridine, 2.
Anabaseine dihydrochloride (200 mg, 0.860 mmol) and 5-iodo-2,4dimethoxybenzaldehyde (350 mg, 1.20 mmol) were mixed in ethanol (11 mL) and
subjected to the general procedure. The resulting mixture was purified via flash
chromatography (SiO2; 5:2 = EtOAc: methanol) to yield 360 mg (97%) of a
yellow solid. Mp = 138-140 °C. 1H NMR (CDCl3): δ 1.87 (t, 2H), 2.76 (m, 2H),
3.77 (s, 3H), 3.88 (t, 2H), 3.91 (s, 3H), 6.38 (s, 1H), 6.79 (s, 1H), 7.36 (dd, J1 =
7.65 Hz, J2 = 4.80 Hz, 1H), 7.70 (s, 1H), 7.89 (dt, J = 7.8 Hz, 1H), 8.66 (dd, J1 =
4.81 Hz, J2 = 1.41 Hz, 1H), and 8.75 (d, J = 1.50 Hz, 1H).

13

C NMR (CDCl3): δ

22.4, 25.5, 50.2, 55.7, 56.4, 73.8, 95.2, 119.3, 122.9, 130.6, 130.8, 135.8, 136.5,
139.4, 149.7, 149.9, 159.2, and 167.2. Anal. Calcd. for C19H19N2O2I: C, 52.55;
H, 4.41; N, 6.45. Found: C, 52.56; H, 4.45; N, 6.43.
9.4.2.4 3-(3-Iodo-4-methoxybenzylidene)-3,4,5,6-tetrahydro-[2,3']bipyridine,
55.
Anabaseine dihydrochloride (162 mg, 0.690 mmol) and 3-iodo-4156

methoxybenzaldehyde (200 mg, 0.760 mmol) were mixed in ethanol (7 mL) and
subjected to the general procedure. The resulting mixture was purified via flash
chromatography (SiO2; 20: 1 = EtOAc: isopropyl alcohol) to yield 262 mg (89%)
of a yellow solid. Mp = 49-50 °C. 1H NMR (CDCl3): δ 1.84 (m, 2H), 2.81 (m,
2H), 3.89 (m, 5H), 6.52 (s, 1H), 6.80 (d, J = 8.52 Hz, 1H), 7.26 (dd, J1 = 8.48 Hz,
J2 = 2.02 Hz, 1H), 7.33 (dd, J1 = 7.74 Hz, J2 = 4.89 Hz, 1H), 7.75 (d, J1 = 2.01
Hz, 1H), 7.81 (dt, J1 = 7.90 Hz, 1H), 8.63 (dd, J1 = 3.48 Hz, J2 = 1.19 Hz, 1H) and
8.72 (d, J1 = 1.31 Hz, 1H).

13

C NMR (CDCl3): δ 22.2, 25.7, 50.2, 56.4, 85.8,

110.4, 123.0, 130.3, 130.9, 131.1, 133.8, 136.1, 136.2, 140.5, 149.6, 149.7, 157.9,
and 166.9. Anal. Calcd. for C18H17N2OI: C, 53.48; H, 4.24; N, 6.93. Found: C,
53.23; H, 4.26; N, 6.87.

9.4.2.5 3-(5-Bromo-2,4-dimethoxybenzylidene)-3,4,5,6-tetrahydro
[2,3']bipyridine, 56.
Anabaseine dihydrochloride (772 mg, 3.30 mmol) and 5-bromo-2,4dimethoxybenzaldehyde (893 mg, 3.60 mmol) were mixed in ethanol (25 mL) and
subjected to the general procedure. The resulting mixture was purified via flash
chromatography (SiO2; EtOAc, 1:1 = EtOAc: isopropanol, 1:2 = EtOAc:
isopropanol, 1:3 = EtOAc: isopropanol) to yield 1.00 g (78 %) of a yellow solid.
Mp = 132.134 °C. 1H NMR (CDCl3): δ 1.83 (m, 2H), 2.73 (m, 2H), 3.76 (s, 3H),
3.89 (t, 2H), 3.92 (s, 3H), 6.43 (s, 1H), 6.70 (s, 1H), 7.32 (dd, J1 = 7.74 Hz, J2 =
4.91 Hz, 1H), 7.47 (s, 1H), 7.82 (dt, J = 7.83 Hz, 1H), 8.62 (dd, J1 = 4.86 Hz, J2 =
1.66 Hz, 1H), and 8.75 (d, J = 1.54 Hz, 1H).
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13

C NMR (CDCl3): δ 22.5, 25.6,

50.5, 55.8, 56.3, 96.1, 101.5, 118.5, 122.9, 129.8, 131.0, 133.5, 136.2, 136.3,
149.6, 149.9, 156.7, 158.0, and 166.8. Anal. Calcd. for C19H19N2O2Br: C, 58.93;
H, 4.95; N, 7.23. Found: C, 58.84; H, 5.02; N, 7.02.

9.4.2.6 3-(5-Iodo-2,4-dimethylbenzylidene)-3,4,5,6-tetrahydro[2,3']bipyridine, 57.
Anabaseine dihydrochloride (258 mg, 1.11 mmol) and 5-iodo-2,4dimethylbenzaldehyde (276 mg, 1.06 mmol) were mixed with ethanol (5 mL) and
subjected to the general procedure. The resulting mixture was purified via flash
chromatography (SiO2; 7:1 = EtOAc: methanol) to yield 227 mg (57%) of a
yellow gummy liquid. 1H NMR (CDCl3): δ 1.82 (m, 2H), 2.05 (s, 3H), 2.38 (s,
3H), 2.62 (m, 2H), 3.92 (t, 2H), 6.58 (s, 1H), 7.06 (s, 1H), 7.33 (dd, J1 = 7.63 Hz,
J2 = 4.84 Hz, 1H), 7.63 (s, 1H), 7.82 (dt, J = 7.81, 1H), 8.63 (dd, J1 = 4.81 Hz, J2
= 1.44 Hz, 1H), and 8.75 (d, J = 1.49, 1H).

13

C NMR (CDCl3): δ 19.2, 22.4, 24.9,

27.4, 50.4, 96.7, 122.8, 131.2, 132.5, 132.6, 134.1, 135.7, 135.9, 136.5, 138.2,
140.7, 149.5, and 166.0. . HRMS: Anal. Calcd. for C19H20IN2, 403.0600. Found
403.0671.

9.4.2.7 5'-Bromo-3-(2,4-dimethoxybenzylidene)-3,4,5,6tetrahydro-[2,3']bipyridine, 58.
5’-Bromoanabaseine dihydrochloride (200 mg, 0.640 mmol) and 2,4dimethoxybenzaldehyde (213 mg, 1.28 mmol) were mixed in ethanol (10 mL) and
subjected to the general procedure. The resulting mixture was purified via flash
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chromatography (SiO2; 20: 1 = EtOAc: isopropyl alcohol) to yield 238 mg (95%)
of a yellow solid. Mp = 83-84 °C. 1H NMR (CDCl3): δ 1.81 (m, 2H), 2.74 (m,
2H), 3.75 (s, 3H), 3.83 (s, 3H), 3.88 (t, 2H), 6.44 (d, J = 2.34 Hz, 1H), 6.51 (dd, J1
= 8.42 Hz, J2 = 2.32 Hz, 1H), 6.78 (s, 1H), 7.25 (d, J = 8.40 Hz, 1H), 8.01 (t, 1H),
and 8.68 (d, J = 2.12 Hz, 2H).

13

C NMR (CDCl3): δ 22.5, 25.6, 50.6, 55.4, 98.3,

104.1, 117.3, 120.2, 129.7, 130.6, 131.3, 138.0, 139.0, 148.1, 150.5, 158.8, 161.3,
and 165.9. Anal. Calcd. for C19H19N2O2Br: C, 58.93; H, 4.95; N, 7.23. Found:
C, 59.14; H, 4.88; N, 7.00.

9.4.2.8 5'-Bromo-3-(2,4-dimethylbenzylidene)-3,4,5,6-tetrahydro[2,3']bipyridine, 59.
5’-Bromoanabaseine dihydrochloride (544 mg, 1.74 mmol) and 2,4dimethylbenzaldehyde (468 mg, 3.49 mmol) were mixed in ethanol (25 mL) and
subjected to the general procedure. The resulting mixture was purified via flash
chromatography (SiO2; EtOAc) to yield 515 mg (83%) of a tan solid. Mp = 67-68
°C. 1H NMR (CDCl3): δ 1.79 (m, 2H), 2.12 (s, 3H), 2.32 (s, 3H), 2.64 (m, 2H),
3.91 (t, 2H), 6.69 (s, 1H), 7.01 (s, 2H), 7.12 (t, 1H), 8.01 (t, 1H), 8.69 (m, 2H).
13

C NMR (CDCl3): δ 19.8, 21.1, 22.6, 25.1, 50.1, 120.3, 126.1, 128.5, 130.9,

131.4, 131.5, 134.8, 136.5, 137.5, 138.0, 138.7, 147.7, 150.6, and 165.3. Anal.
Calcd. for C19H19N2Br: C, 64.23; H, 5.39; N, 7.89. Found: C, 63.96; H, 5.35; N,
7.83.
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9.5 EXPERIMENTAL PROCEDURES FOR THE SYNTHESIS OF
BENZALDEHYDE BORONIC ESTERS

9.5.1 General Procedure for the Synthesis of Benzaldehyde Boronic Esters
A halogenated benzaldehyde derivative (1 eq), [1, 1’bis(diphenylphosphino)ferrocene] dichloropalladium (0.03 eq),
bis(pinacolato)diboron (1.1 eq), and potassium acetate (3 eq) were placed in a 10
mL round bottom flask equipped with a short adapter and septum. The apparatus
was placed on high vacuum for at least 3 hours while stirring the solids
occasionally. The apparatus was backfilled with argon, injected with DMSO, and
heated to 80 °C. The reaction was monitored by TLC until very little or no
starting material remained. Upon completion, the reaction mixture was cooled to
room temperature, quenched with brine and extracted twice with ethyl acetate.
The combined organic layers were washed three times with brine, dried over
anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure.
The resulting mixture was then purified by flash chromatography as specified in
the analytical section for each specific compound.

9.5.2 Analytical Data for Benzaldehyde Boronic Esters

9.5.2.1 3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)benzaldehyde, 68.133
3-Iodobenzaldehyde (300 mg, 1.29 mmol) was subjected to the general
procedure using 5 mL DMSO. The reaction time was 1.5 hours. Flash
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chromatography (SiO2; hexanes, then 10:1 = hexanes: THF) was performed to
yield 180 mg (60%) of a clear liquid. 1H NMR (CDCl3): δ 1.36 (s, 12H), 7.53 (t,
1H), 7.98 (dd, J1 = 7.78 Hz, J2 = 1 Hz, 1H), 8.06 (dd, J1 = 7.30 Hz, J2 = 1 Hz,
1H), 8.30 (s, 1H), and 10.04 (s, 1H).

13

131.3, 135.8, 137.2, 140.6, and 192.5.

C NMR (CDCl3): δ 24.9, 64.2, 128.4,

11

B NMR (CDCl3): δ 31.65.

9.5.2.2 4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)benzaldehyde, 69.133
4-Bromobenzaldehyde (500 mg, 2.70 mmol) was subjected to the general
procedure using 3 mL DMSO. The reaction time was 3 hours. Flash
chromatography was performed (Al2O3; hexanes, then 10:1 = hexanes: EtOAc) to
yield 175 mg (28%) of a white solid. Mp = 60-61 °C. 1H NMR (CDCl3): δ 1.36 (s,
12H), 7.86 (d, J = 7.75 Hz, 2H), 7.96 (d, J = 7.75 Hz), and 10.05 (s, 1H).

13

C

NMR (CDCl3): δ 24.9, 84.3, 128.6, 135.2, 138.1, and 192.6.

9.5.2.3 2,4-Dimethoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)
benzaldehyde, 70.
5-Iodo-2, 4-dimethyoxybenzaldehyde (500 mg, 1.71 mmol) was subjected
to the general procedure using 5 mL DMSO. The reaction time was 3 hours.
Flash chromatography was performed (Al2O3; hexanes, then 5: 3 = hexanes:
EtOAc) to yield 333 mg (67%) of a white solid. Mp = 144-146 °C. 1H NMR
(CDCl3): δ 1.33 (s, 12H), 3.92 (s, 3H), 3.95 (s, 3H), 6.36 (s, 1H), 8.21 (s, 1H), and
10.25 (s, 1H).

13

C NMR (CDCl3): δ 24.8, 55.5, 56.0, 83.5, 93.5, 118.3, 139.4,
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166.0, 170.7, and 188.2.

11

B NMR (CDCl3): δ 31.3. Anal. Calcd. for

C15H21BO5: C, 61.67; H, 7.25. Found: C, 61.66; H, 7.35.

9.5.2.4 4-Methoxy-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)
benzaldehyde, 71.148
4-Methoxy-3-iodobenzaldehyde (300 mg, 1.14 mmol) was subjected to the
general procedure using 5 mL DMSO. The reaction time was 1.5 hours. Flash
chromatography (SiO2; hexanes, then a small amount of CH2Cl2, then 5:2 =
hexanes: THF) was performed to yield 258 mg (86%) of a white solid. Mp = 9092 °C. 1H NMR (CDCl3): δ 1.36 (s, 12H), 3.92 (s, 3H), 6.96 (d, J = 8.77 Hz, 1H),
7.95 (d, J = 8.66, 1H), 8.20 (s, 1H), and 9.90 (s, 1H).

13

C NMR (CDCl3): δ 24.8,

56.0, 83.9, 110.5, 129.3, 134.1, 139.9, 168.8, and 190.9.

11

B NMR (CDCl3): δ

31.56.

9.5.2.5 2,4-Dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)
benzaldehyde, 72.
2, 4-Dimethyl-5-iodobenzaldehyde (300 mg, 1.149 mmol) was subjected
to the general procedure using 5 mL DMSO. The reaction time was 6 hours.
Flash chromatography was performed (Al2O3; hexanes, then 30: 1 = hexanes:
EtOAc) to yield 128 mg (43%) of a white solid. Mp = 63-64 °C. 1H NMR
(CDCl3): δ 1.35 (s, 12H), 2.56 (s, 3H), 2.63 (s, 3H), 7.06 (s, 1H), 8.17 (s, 1H), and
10.17 (s, 1H).

13

C NMR (CDCl3): δ 20.0, 22.4, 25.0, 63.7, 131.4, 133.5, 141.8,
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142.9, 151.3, and 193.1.

11

B NMR (CDCl3): δ 32.0. Anal. Calcd. for

C15H21BO3: C, 69.26; H, 8.14. Found: C, 68.64; H, 8.16.

9.6 EXPERIMENTAL PROCEDURES FOR THE SYNTHESIS OF
POTASSIUM BENZYLIDENE ANABASEINE TRIFLUOROBORATE
SALTS

9.6.1 General Procedure for the Synthesis of Potassium Benzylidene
Anabaseine Trifluoroborate Salts Using Strategy A
A halogenated benzilidene anabaseine derivative (1eq), [1, 1’bis(diphenylphosphino)ferrocene]dichloropalladium (0.03 eq),
bis(pinacolato)diboron (1.1 eq), and potassium acetate (3eq) were placed in a 10
mL round bottom flask equipped with a short adapter and septum. The apparatus
was placed on high vacuum for three hours while stirring and gently heating with
a heat gun three times. The apparatus was backfilled with argon, injected with
DMSO (4 mL), and heated to 95 °C. The reaction was monitored via TLC until
no starting material remained. The DMSO was then removed via Kugelrohr
distillation at 80 °C. The solid was dissolved in boiling ethyl acetate and filtered.
The filtrate was concentrated and the residual solid was dissolved in methanol (5
mL). Potassium hydrogen fluoride (4 eq) was dissolved in water (2ml) and then
transferred via pipette to the mixture that was stirred at room temperature in open
air for 4 hours. The solvents were removed under reduced pressure and then high
vacuum. The residual solid was dissolved in boiling acetonitrile. The mixture
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was then filtered to remove excess potassium hydrogen fluoride. The filtrate was
evaporated under reduced pressure and then high vacuum. The residual solid was
thenrinsed with boiling ethyl acetate and filtered to give the solid product. Yields
are displayed in Table 5.3.

9.6.2 General Procedure for the Synthesis of Potassium Benzylidene
Anabaseine Trifluoroborate Salts Using Strategy B
A benzaldehyde boronic ester derivative (1 eq) and anabaseine
dihydrochloride (1.1 eq) were added to ethanol (10 mL) and allowed to react at 80
°C. The reaction was monitored via TLC and stopped after the benzaldehyde was
no longer observed. The ethanol was removed under reduced pressure and the
solid was dissolved in water (20 mL). Triethylamine (2 mL) was added dropwise
and the mixture stirred for 10 min. The mixture was extracted with EtOAc (2 x
50 mL). The organic layer was concentrated under reduced pressure without
drying and diluted with methanol (5mL). Potassium hydrogen fluoride (4 eq) was
dissolved in water (2mL) and then transferred via pipette to the mixture which
was stirred at room temperature in open air for 4 hours. The solvents were
removed under reduced pressure and then high vacuum. The residual solid was
dissolved in boiling acetonitrile and filtered to remove excess potassium hydrogen
fluoride. The filtrate was evaporated under reduced pressure and then high
vacuum. The residual solid was then rinsed with boiling ethyl acetate and filtered
to give the solid product. Yields are displayed in Table 6.2.
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9.6.3 Analytical Data of Benzylidene Anabaseine Trifluoroborate Salts

9.6.3.1 3-(3-Trifluoroborobenzylidene)-3,4,5,6-tetrahydro-[2,3']bipyridine
Potassium Salt, 61.
Mp = 138-140 °C (decomposition). 1H NMR (DMSO-d6): δ 1.82 (m,
2H),
2.86 (m, 2H), 3.77 (m, 2H), 6.72 (s, 1H), 7.16 (d, J = 6.00 Hz, 2H), 7.35 (d J =
6.90 Hz, 2H), 7.52 (dd, J1 = 7.12 Hz, J2 = 4.86 Hz, 1H), 7.91 (dt, J = 6.08 Hz,
1H), and 8.69 (s, 2H).

13

C NMR (DMSO-d6): δ 21.3, 24.9, 48.0, 123.1, 126.5,

126.9, 129.5, 132.4, 132.8, 133.5, 133.7, 136.5, 141.3, 149.2, 150.3, and 168.6.
11

B NMR (DMSO-d6): δ 4.46. 19F NMR (DMSO-d6): δ -139.9. HRMS: Anal.

Calcd. for C17H15N2BF3, 315.1284. Found 315.1290.

9.6.3.2 3-(4-Trifluoroborobenzylidene)-3,4,5,6-tetrahydro-[2,3']bipyridine
Potassium Salt, 62.
Mp = 150-152 °C (decomposition). 1H NMR (DMSO-d6): δ 1.83 (m,
2H), 2.88 (m, 2H), 3.76 (m, 2H), 6.74 (s, 1H), 7.20 (d, J = 7.20 Hz, 2H), 7.39 (d,
J = 7.60 Hz, 2H), 7.53 (t, 1H), 7.93 (d, J = 6.80 Hz, 1H), and 8.70 (s, 2H).

13

C

NMR (DMSO-d6): δ 21.1, 24.9, 47.6, 123.2, 128.6, 129.1, 131.5, 133.2, 136.7,
141.9, 149.2, 150.5, and 169.2.

11

B NMR (DMSO-d6): δ 4.21.

19

F NMR

(DMSO-d6): δ -139.9. HRMS: Anal. Calcd. for C17H15N2BF3, 315.1284. Found
315.1301.
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9.6.3.3 3-(5-Trifluoroboro-2,4-dimethyoxybenzylidene)-3,4,5,6-tetrahydro[2,3']bipyridine Potassium Salt, 63.
Mp = 117-118 °C (decomposition). 1H NMR (DMSO-d6): δ 1.84
(m, 2H), 2.80 (m, 2H), 3.66 (s, 3H), 3.70 (s, 3H), 3.79 (m, 2H), 3.36 (s, 1H), 7.00
(s, 1H), 7.51 (m, 2H), 7.91 (d, J = 7.69 Hz, 1H), and 8.69 (m, 2H).

13

C NMR

(DMSO-d6): δ 21.1, 24.9, 47.1, 54.9, 55.4, 94.4, 114.1, 123.0, 126.1, 133.1,
135.2, 136.7, 138.5, 149.2, 150.5, 158.5, 166.2, and 169.2.
4.11.

11

B NMR (CD3CN): δ

19

F NMR (DMSO-d6): δ -137.0. HRMS: Anal. Calcd. for

C19H19N2O2BF3, 375.150. Found 375.150.

9.6.3.4 3-(3-Trifluoroboro-4-methyoxybenzylidene)-3,4,5,6-tetrahydro[2,3']bipyridine Potassium Salt, 64.
Mp = 162-163 °C (decomposition). 1H NMR (DMSO-d6): δ 1.73 (m,
2H), 2.79 (t, 2H), 3.64 (s, 3H), 3.71 (t, 2H), 6.48 (s, 1H), 6.72 (d, J = 8.44 Hz,
1H), 7.13 (dd J1 = 8.42 Hz, J2 = 1.88 Hz, 1H), 7.30 (d, J = 1.80, 1H), 7.43 (dd, J1
= 7.45 Hz, J2 = 4.83 Hz, 1H), 7.82 (d, J = 7.77, 1H), and 8.61 (s, 2H).

13

C NMR

(DMSO-d6): δ 21.8, 25.6, 49.0, 54.7, 109.4, 123.0, 126.2, 127.7, 129.0, 135.8,
136.1, 137.1, 149.1, 149.4, 163.1, and 167.1.

11

B NMR (DMSO-d6): δ 2.31.

NMR (DMSO-d6): δ -137.7. HRMS: Anal. Calcd. for C18H17N2OBF3,
345.1389. Found 345.1379.
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F

9.6.3.5 3-(5-Trifluoroboro-2,4-dimethylbenzylidene)-3,4,5,6-tetrahydro[2,3']bipyridine Potassium Salt, 65.
Mp = 113-115 °C (decomposition). 1H NMR (CD3OD): δ 1.96 (s, 3H),
2.01 (t, 2H), 2.34 (t, 2H), 2.98 (t, 2H), 3.81 (t, 2H), 6.86 (s, 1H), 7.37 (s, 1H), 7.60
(dd, J1 = 8.00 Hz, J2 = 4.80 Hz, 1H), 7.65 (s, 1H), 8.03 (d, J = 8.00 Hz, 1H), 8.74
(s, 1H), and 8.77 (d, J = 4.80, 1H).

13

C NMR (CD3OD): δ 19.5, 21.2, 22.2, 25.2,

46.4, 125.1, 129.1, 129.8, 130.9, 132.6, 135.0, 138.3, 139.1, 148.4, 150.0, 153.6,
154.7, and 176.0.

11

B NMR (CD3OD): δ 5.29. HRMS: Anal. Calcd. for

C19H19N2BF3, 343.2. Found 343.3.

9.6.3.6 3-(2,4-Dimethyoxybenzylidene)-5’-trifluoroboro-3,4,5,6-tetrahydro[2,3']bipyridine Potassium Salt, 66.
Mp = 139-140 °C (decomposition). 1H NMR (DMSO-d6): δ 1.84 (m,
2H), 2.79 (m, 2H), 3.69 (s, 3H), 3.72 (m, 2H), 3.80 (s, 3H), 6.58 (d, J = 2.13 Hz,
1H) 6.62 (dd, J1 = 8.52 Hz, J2 = 2.13 Hz, 1H), 7.05 (s, 1H), 7.44 (d, J = 8.54 Hz,
1H), 7.78 (s, 1H), 8.42 (d, J = 2.12 Hz, 1H), and 8.59 (s, 1H). ).

13

C NMR

(DMSO-d6): δ 20.8, 24.4, 46.5, 55.5, 55.6, 98.2, 105.4, 116.0, 128.2, 130.3,
131.3, 136.2, 139.7, 146.3, 154.1, 159.4, 162.4, and 171.6.
d6): δ 3.98.

19

11

B NMR (DMSO-

F NMR (DMSO-d6): δ -139.7. HRMS: Anal. Calcd. for

C19H19N2O2BF3, 375.1495. Found 375.1489.
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9.6.3.7 3-(2,4-Dimethylbenzylidene)-5’-trifloroboro-3,4,5,6-tetrahydro[2,3']bipyridine Potassium Salt, 67.
Mp = 186-187 °C (decomposition). 1H NMR (DMSO-d6): δ 1.73 (m,
2H), 2.06 (s, 3H), 2.27 (s, 3H), 2.59 (m, 2H), 3.76 (t, 2H), 6.69 (s, 1H), 7.05 (m,
2H), 7.20 (d, J = 7.89 Hz, 1H), 7.77 (s, 1H), 8.40 (s, 1H), and 8.51 (s, 1H).

13

C

NMR (DMSO-d6): δ 19.3, 20.7, 22.0, 24.5, 49.0, 126.1, 128.5, 130.7, 131.6,
133.1, 134.7, 136.3, 137.4, 139.1, 146.0, 152.7, and 167.9. .
d6): δ 4.16.

11

B NMR (DMSO-

19

F NMR (DMSO-d6): δ -139.6. HRMS: Anal. Calcd. for

C19H19N2BF3, 343.1597. Found 343.1590.

9.7 EXPERIMENTAL PROCEDURES FOR THE HALOGENATION OF
BENZYLIDENE ANABASEINE TRIFLUOROBORATE SALTS

9.7.1 General Procedure for the Halogenation of Benzylidene Anabaseine
Potassium Trifluoroborate Salts
To a 5 ml round bottom flask, a benzylidene anabaseine potassium
trifluoroborate salt was added (1 eq). A 50% aqueous THF solution (0.5 mL) was
then added and the mixture was stirred until the solid dissolved. Sodium iodide or
ammonium bromide (1 eq) and then peracetic acid or chloramine-T (1 eq) was
sequentially added. The mixture was covered with aluminum foil and stirred for
30 min. A 10% aqueous sodium thiosulfate solution (5 drops) was then added.
The reaction mixture was then transferred to a separatory funnel, quenched with
water (15 mL), and extracted into dichloromethane (2 x 15 mL). The organic
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layers were then dried over anhydrous magnesium sulfate, filtered, and
concentrated under reduced pressure. For halogenations producing compounds
which have not already been described in section 9.4, purification via flash
chromatography was performed as specified in the analytical section for each
specific compound. Yields are displayed in Table 7.1 and Table 7.2.

9.7.2 Analytical Data for Halogenated Benzylidene Anabaseine Derivatives

9.7.2.1 3-(5-Bromo-2,4-dimethylbenzylidene)-3,4,5,6-tetrahydro[2,3']bipyridine, 78.
3-(5-Trifluoroboro-2,4-dimethylbenzylidene)-3,4,5,6-tetrahydro[2,3']bipyridine potassium salt (10 mg, 0.026 mmol) was subjected to the general
procedure using ammonium bromide and peracetic acid as the oxidant. The
resulting mixture was purified via flash chromatography (SiO2; 7:1 = EtOAc:
methanol) to yield 5 mg (55%) of a yellow gummy liquid. 1H NMR (CDCl3): δ
1.82 (m, 2H), 2.06 (s, 3H), 2.36 (s, 3H), 2.63 (m, 2H), 3.92 (t, 2H), 6.60 (s, 1H),
7.05 (s, 1H), 7.34 (dd, J1 = 7.53 Hz, J2 = 5.05 Hz, 1H), 7.37 (s, 1H), 7.83 (dt, J =
7.81, 1H), 8.64 (d, J = 3.83, 1H), and 8.76 (s, 1H).

13

C NMR (CDCl3): δ 19.3,

22.6, 25.2, 29.7, 121.4, 123.1 132.0, 132.5, 132.7, 133.5, 134.1, 135.8, 136.2,
137.5, 149.7, 149.8, and 166.5. HRMS: Anal. Calcd. for C19H20BrN2, 355.0811.
Found 355.0745.
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9.7.2.2 3-(3-Bromo-4-methoxybenzylidene)-3,4,5,6-tetrahydro[2,3']bipyridine, 77.
3-(3-Trifluoroboro-4-methyoxybenzylidene)-3,4,5,6-tetrahydro[2,3']bipyridine potassium salt (20 mg, 0.052 mmol) ) was subjected to the
general procedure using ammonium bromide and peracetic acid as the oxidant.
The resulting mixture was purified via flash chromatography (SiO2; 5: 1 =
EtOAc: methanol) to yield 15 mg (81%) of a yellow solid. Mp = 35-36 °C. 1H
NMR (CDCl3): δ 1.85 (m, 2H), 2.83 (m, 2H), 3.89 (m, 5H), 6.54 (s, 1H), 6.89 (d,
J = 8.40 Hz, 1H), 7.22 (dd, J1 = 8.40 Hz, J2 = 1.8 Hz, 1H), 7.34 (dd, J1 = 7.50 Hz,
J2 = 5.1 Hz, 1H), 7.53 (d, J1 = 2.40 Hz, 1H), 7.81 (dt, J1 = 7.5 Hz, 1H), 8.64 (d, J
= 3.30 Hz, 1H) and 8.73 (s, 1H).

13

C NMR (CDCl3): δ 22.1, 25.7, 50.1, 56.3,

111.5, 123.1, 130.0, 130.1, 131.1, 134.3, 136.2, 136.3, 149.7, 155.6, and 167.0.
HRMS: Anal. Calcd. for C18H18N2OBr, 357.0602. Found 357.0549.

9.8 EXPERIMENTAL PROCEDURES FOR THE RADIOLABELING OF
BENZYLIDENE ANABASEINE TRIFLUOROBORATE SALTS

9.8.1 General Procedure for the Radiobromination of Benzylidene
Anabaseine Potassium Trifluoroborate Salts
NH476Br (35 - 65 µCi in 0.1% aqueous NH4OH) was placed in a 2 ml
Wheaton vial containing a trifluoroborate (100 µL of 2.5 x 10 -2 M solution in
50% aqueous tetrahydrofuran). To this, sodium bromide (100 µL of 2.5 x 10 -2 M
solution in water) and peracetic acid (100 µL, 0.3% solution in methanol) or
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chloramine-T (100 µL of 2.5 x 10 -2 M solution in 50% aqueous tetrahydrofuran)
was sequentially added. The reaction vial was sealed, covered with aluminum foil,
and the mixture stirred for 25 min at room temperature. The radiobrominated
product was isolated by passing the reaction mixture through a Sep-pak cartridge
to remove ionic material, using solvent systems specified in the following
analytical sections as eluent. Radiochemical yields and purity were determined
by radio-TLC analyses.

9.8.2 Analytical Data for Radiobrominated Benzylidene Anabaseine
Derivatives

9.8.2.1 3-(5-[76Br]Bromo-2,4-dimethylbenzylidene)-3,4,5,6-tetrahydro
[2,3']bipyridine, 79.
Radiobromination was performed using both peracetic acid and
chloramine-T as noted according to the general procedure and eluted with a 5:1
dichloromethane: isopropanol solution. The use of chloramine-T resulted in a
radiochemical yield of 40% and a radiochemical purity of 98.96%. The use of
peracetic acid resulted in a radiochemical yield of 65% and a radiochemical purity
of 90.77%.

171

9.8.2.2 3-(5-[76Br]Bromo-2,4-dimethoxybenzylidene)-3,4,5,6-tetrahydro
[2,3']bipyridine, 80.
Radiobromination was performed using both peracetic acid and
chloramine-T as noted according to the general procedure and eluted with a 5:1
EtOAc: methanol solution. The use of chloramine-T resulted in a radiochemical
yield of 57% and a radiochemical purity of 82.75%. The use of peracetic acid
resulted in a radiochemical yield of 47% and a radiochemical purity of 84.68%.

9.8.3 Synthesis of 3-(5-[123I] Iodo-2,4-dimethyoxybenzylidene)3,4,5,6-tetrahydro-[2,3']bipyridine, 81.
No-carrier-added Na123I (247 µCi in 0.1% aqueous NaOH) was placed in a
2 ml Wheaton vial containing 3-(5-trifluoroboro-2,4-dimethyoxybenzylidene)3,4,5,6-tetrahydro-[2,3']bipyridine potassium salt (100 µL of 2.5 x 10 -2 M
solution in 50% aqueous tetrahydrofuran). To this was added peracetic acid (100
µL, 0.3% solution in methanol). The reaction vial was sealed, covered with
aluminum foil, and the mixture stirred for 30 min at room temperature. The
radioiodinated product was isolated by passing the reaction mixture through a
Sep-pak cartridge to remove ionic material using 5: 2 EtOAc: methanol as eluent.
Radiochemical yields and purity were determined by radio-TLC analyses
(aluminum backed silica gel plate; EtOAc- methanol 5: 2). The radiochemical
yield was determined to be 94% and the radiochemical purity was 91.91%.
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9.9 EXPERIMENTAL PROCEDURE FOR SPECT IMAGING 149
Eight-week-old male outbred Syrian golden hamsters were subcutaneously
injected with NNK at a dosage of 2.5 mg in 0.1 mL saline per 100 g bodyweight
three times a week for 10 weeks. Age-matched controls were given identical
injections with the vehicle (saline). One day after the last injection, an NNKtreated hamster and control hamster was weighed and then injected
subcutaneously in the right inguinal region with 100 µL of a saline solution
containing 100 µCi (3.7 MBq) of iodine-123 labeled analogue 81. Twenty min
after injection of the tracer, the NNK treated and the control hamster were
sacrificed by CO2 asphyxiation. A whole-body planar nuclear medicine image of
each hamster was obtained using an Argus Epic gamma camera (Phillips Medical
Systems Inc.) equipped with a pinhole collimator. Images were obtained using a
128 x 128 matrix for 10 min with a photopeak centered at a 159 keV±10% energy
window.
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